Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 1538. Отображено 100.
10-05-2012 дата публикации

Smac mimetec

Номер: US20120115922A1
Автор: Matthew G. Laporte, Stephen M. Condon, Susan R. Rippin, Yijun Deng
Принадлежит: TETRALOGIC PHARMACEUTICALS CORP

A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Подробнее
Номер записи: 1
10-01-2013 дата публикации

SMAC Mimetic

Номер: US20130012564A1
Автор: Matthew G. Laporte, Stephen M. Condon, Susan R. Rippin, Yijun Deng
Принадлежит: TETRALOGIC PHARMACEUTICALS CORP

A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Подробнее
Номер записи: 2
28-11-2013 дата публикации

Method for stem cell differentiation in vivo by delivery of morphogenes with mesoporous silica and corresponding pharmceutical active ingredients

Номер: US20130315962A1
Автор: Alfonso E. Garcia-Bennett, Elena Nickolaevna Kozlova
Принадлежит: Nanologica AB

A pharmaceutical active ingredient for cell differentiation to alleviate cell and cell-related deficiencies in mammals comprising porous silica containing a releasable agent capable of contributing to a cell environment conducive for stem cell differentiation in co-implanted stem cells and/or in endogenous stem cells.

Подробнее
Номер записи: 3
07-01-2016 дата публикации

CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION

Номер: US20160002593A1
Автор: MEIER Steven J., VARMA Sharat, VIJAYASANKARAN Natarajan, Yang Yi
Принадлежит: Genentech, Inc.

Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided. 1. A method of culturing a cell comprising a nucleic acid encoding a polypeptide , wherein the method comprises the step of contacting the cell with a cell culture medium comprising hypotaurine or an analog or precursor thereof , wherein the cell culture medium comprising the hypotaurine or an analog of precursor thereof reduces the color intensity of a composition comprising the polypeptide produced by the cell as compared to the color intensity of a composition comprising the polypeptide produced by the cell cultured in a cell culture medium that does not comprise the hypotaurine or an analog or precursor thereof.2. The method of claim 1 , wherein the cell culture medium comprising the hypotaurine or an analog or precursor thereof reduces the color intensity of a composition comprising the polypeptide produced by the cell by at least about 0.1% as compared to a composition comprising the polypeptide produced by the cell cultured in a cell culture medium that does not comprise the hypotaurine or an analog or precursor thereof.3. The method of claim 1 , wherein the cell culture medium comprising the hypotaurine or an analog or precursor thereof reduces the color intensity of a composition comprising the polypeptide produced by the cell by about 5% to about 50% as compared to a composition comprising the polypeptide produced by the cell cultured in a cell culture medium that does not comprise the hypotaurine or an analog or precursor thereof.43. The method of any one of - claims 1 , wherein the cell culture medium comprises the hypotaurine or an analog or precursor thereof at a concentration of at least about 0.0001 mM.5. The method of claim 4 , wherein the cell culture medium comprises the ...

Подробнее
Номер записи: 4
05-01-2017 дата публикации

METHODS OF GENERATING NATURAL KILLER CELLS

Номер: US20170002322A1
Автор: Hariri Robert J., Heidaran Mohammad A., JASKO Stephen, KANG Lin, LAW Eric, PAL Ajai, STOUT Bhavani, VOSKINARIAN-BERSE Vanessa, ZEITLIN Andrew, ZHANG Xiaokui
Принадлежит: Anthrogenesis Corporation

Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection. 1. A method of producing a population of activated natural killer (NK) cells , comprising:(a) seeding a population of hematopoietic stem or progenitor cells in a first medium comprising interleukin-15 (IL-15) and, optionally, one or more of stem cell factor (SCF) and interleukin-7 (IL-7), wherein said IL-15 and optional SCF and IL-7 are not comprised within an undefined component of said medium, such that the population expands, and a plurality of hematopoietic stem or progenitor cells within said population of hematopoietic stem or progenitor cells differentiate into NK cells during said expanding; and(b) expanding the cells from the step (a) in a second medium comprising interleukin-2 (IL-2), to produce a population of activated NK cells.2. A two-step method of producing a population of activated natural killer (NK) cells , wherein a first step of said method comprises expanding a population of hematopoietic stem or progenitor cells in a first medium comprising one or more of stem cell factor (SCF) , interleukin-7 (IL-7) and interleukin-15 (IL-15) , and wherein said SCF , IL-7 and IL-15 are not comprised within an undefined component of said medium , and wherein a plurality of hematopoietic stem or progenitor cells within said population of hematopoietic stem or progenitor cells differentiate into NK cells during said expanding; andwherein a second step of said method comprises expanding the cells from the first step in a second medium comprising interleukin-2 (IL-2), to produce activated NK cells.3. The method of claim 1 , wherein the first medium further comprises one or more of Fms-like-tyrosine ...

Подробнее
Номер записи: 5
05-01-2017 дата публикации

MEDIUM FOR THE PROTEIN-FREE AND SERUM-FREE CULTIVATION OF CELLS

Номер: US20170002392A1
Автор: Dorner Friedrich, Grillberger Leopold, Mitterer Artur, Mundt Wolfgang, Reiter Manfred
Принадлежит:

A medium is described for the protein-free and serum-free cultivation of cells, especially mammalian cells, whereby the medium contains a proportion of soy hydrolysate. 1. An animal protein-free and serum-free cell culture medium , the medium comprising a soy hydrolysate having a total nitrogen content of between 7.6% and 11.4% , and the medium comprising0.001-1 g/L L-asparagine,0.001-1 g/L L-cysteine,0.001-1 g/L L-cystine,0.001-1.5 g/L L-proline,0.001-1 g/L L-tryptophan, and0.05-1 g/L L-glutamine.2. The animal protein-free and serum-free cell culture medium of claim 1 , wherein the medium comprises an endotoxin content of <500 U/g.3. The animal protein-free and serum-free cell culture medium of claim 1 , wherein the medium comprises more than 10 wt. % ultrafiltered soy hydrolysate based on the total dry weight of the medium claim 1 , and wherein at least 40% of the soy hydrolysate has a molecular weight of ≦500 daltons.4. The animal protein-free and serum-free cell culture medium of claim 3 , wherein at least 50% of the soy hydrolysate has a molecular weight of ≦500 daltons.5. The animal protein-free and serum-free cell culture medium of claim 3 , wherein at least 55% of the soy hydrolysate has a molecular weight of ≦500 daltons.6. The animal protein-free and serum-free cell culture medium of claim 1 , wherein the medium contains ultrafiltered soy hydrolysate.7. The animal protein-free and serum-free cell culture medium of claim 1 , wherein the medium comprises an amino acid.8. The animal protein-free and serum-free cell culture medium of claim 7 , wherein the amino acid is selected from the group consisting of L-asparagine claim 7 , L-cysteine claim 7 , L-cystine claim 7 , L-proline claim 7 , L-tryptophan claim 7 , L-glutamine and mixtures thereof.9. The animal protein-free and serum-free cell culture medium of claim 1 , wherein the animal protein-free and serum-free cell culture medium further comprises: 1 to 100 g/L synthetic minimal medium; 0.05-1 g/L glutamine ...

Подробнее
Номер записи: 6
03-01-2019 дата публикации

CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION

Номер: US20190002822A1
Автор: MEIER Steven J., VARMA Sharat, VIJAYASANKARAN Natarajan, Yang Yi
Принадлежит: Genentech, Inc.

Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided. 163-. (canceled)65. The method of claim 64 , wherein the cell culture medium comprising the one or more of components (a)-(g) reduces the color intensity of the composition comprising the recombinant polypeptide produced by the cells by at least about 0.1% as compared to the composition comprising the recombinant polypeptide produced by the cell cultured in a cell culture medium that does not comprise the one or more of components (a)-(g).66. The method of claim 64 , wherein the cell culture medium comprising the one or more of components (a)-(g) reduces the color intensity of the composition comprising the recombinant polypeptide produced by the cells by about 5% to about 50% as compared to the composition comprising the recombinant polypeptide produced by the cell cultured in a cell culture medium that does not comprise the one or more of components (a)-(g).67. The method of claim 64 , wherein the cell culture medium comprises the one or more components (a)-(g) in an amount selected from the group consisting of:(a) hypotaurine at a concentration from at least about 0.0001 mM;(b) s-carboxymethylcysteine at a concentration from at least about 0.0001 mM;(c) carnosine at a concentration from at least about 0.0001 mM;(d) anserine at a concentration from at least about 0.0001 mM;(e) butylated hydroxyanisole at a concentration from at least about 0.0001 mM;(f) lipoic acid at a concentration from at least about 0.0001 mM; and(g) quercitrin hydrate at a concentration from at least about 0.0001 mM.68. The method of claim 67 , wherein the cell culture medium comprises hypotaurine at a concentration from about 2.0 mM to about 50.0 mM.69. The method of claim 67 , wherein the cell culture medium comprises ...

Подробнее
Номер записи: 7
14-01-2021 дата публикации

PANCREATIC CELLS FOR TREATING DIABETES AND METHODS OF GENERATING THE SAME

Номер: US20210008122A1
Автор: Rust William L.
Принадлежит: Seraxis, Inc.

The present disclosure provides cell-based compositions for treating diabetes, methods for identifying cells that preferentially differentiate into endoderm cells, and methods for preparing insulin-producing pancreatic cells, as well as related methods of use for treating diseases related to insulin deficiency. 1. A method of producing mammalian insulin-secreting cells , comprising:a. culturing mammalian stem cells in adhesion, thereby allowing the mammalian stem cells to spontaneously form three-dimensional structures; andb. culturing of the three-dimensional structures in suspension;wherein the culturing steps comprise at least a 20-day exposure to retinoic acid and cyclopamine, and do not comprise exposing the stem cells of three-dimensional structures to Wnt3A.2. The method of claim 1 , wherein the mammalian stem cells are human stem cells.3. The method of claim 1 , wherein the mammalian stem cells are non-human primate stem cells.4. The method of claim 1 , wherein the mammalian stem cells were derived from a cell line.5. A method of producing insulin-secreting cells claim 1 , comprising:a. culturing mammalian stem cells on an adhesive substrate in a first medium comprising Activin-A and Wortmannin, wherein the mammalian stem cells are not exposed to Wnt3a;b. further culturing the cells in at least one additional medium comprising retinoic acid and cyclopamine; andc. transferring the cells to a suspension culture when the cells form three-dimensional cell structures;wherein the cells are exposed to retinoic acid and cyclopamine for at least 20 days.6. The method of claim 5 , wherein the mammalian stem cells form three-dimensional structures when cultured on the adhesive substrate.7. The method of claim 5 , wherein the mammalian stem cells are human stem cells.8. The method of claim 5 , wherein the mammalian stem cells are non-human primate stem cells.9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. (canceled)16. (canceled)17 ...

Подробнее
Номер записи: 8
12-01-2017 дата публикации

Method Of Differentiation From Stem Cells To Hepatocytes

Номер: US20170009203A1
Автор: Hiroyuki Mizuguchi, Kenji Kawabata, Miho Furue, Mitsuru Inamura
Принадлежит: JAPAN HEALTH SCIENCES FOUNDATION

Disclosed are: a gene transduction method for use in the induction of the differentiation of stem cells such as ES cells or iPS cells into hepatocytes effectively; stem cells into each of which a gene useful for the induction of the differentiation into hepatocytes is introduced; and hepatocytes produced from stem cells each having the gene introduced therein. A specific gene can be introduced into stem cells such as ES cells or iPS cells using an adenovirus vector. The effective induction of the differentiation into hepatocytes can be achieved by introducing the gene. Specifically, the effective induction of the differentiation of stem cells such as ES cells or iPS cells into hepatocytes can be achieved by introducing at least one gene selected from HEX gene, HNF4A gene, HNF6 gene and SOX17 gene into the stem cells.

Подробнее
Номер записи: 9
11-01-2018 дата публикации

A DIRECT CONVERSION METHOD OF HUMAN FIBROBLASTS INTO NEURAL STEM CELLS USING SMALL MOLECULES

Номер: US20180010094A1
Автор: CHOI Kyung-Ah, HONG Sung Hoi, HWANG In Sik
Принадлежит:

The present invention relates to a method of converting human fibroblasts into neural stem cells, and more particularly, to a method of directly converting human fibroblasts into neural stem cells using only a combination of small-molecule compounds without any introduction of a foreign gene, and to the use of the neural stem cells. The method of directly converting human fibroblasts into neural stem cells using only small-molecule compounds without any introduction of a foreign gene makes it possible to obtain genetically stable neural stem cells in an amount sufficient for use in cell therapy by deriving them from human fibroblasts. The neural stem cells obtained according to the method of the present invention can differentiate into functional neural cells and are not tumorigenic. Thus, these neural stem cells are useful as cellular therapeutic agents for treatment of brain diseases. 1. A method for producing neural stem cells , the method comprising:culturing human fibroblasts in a medium comprising Thiazovivin, Valproic acid, Purmorphamine, A8301, SB431542 and CHIR99021.2. The method of claim 1 , wherein the medium further comprises either DZNep (Deazaneplanocin A) or 5-AZA.3. The method of claim 2 , wherein the medium further comprises one or more small-molecule compounds selected from the group consisting of PD0325901 claim 2 , ascorbic acid claim 2 , PS48 claim 2 , forskolin claim 2 , and tranylcypromine.4. The method of claim 1 , wherein the medium is a DMEM/F12 containing N2 claim 1 , B27 claim 1 , bFGF claim 1 , and EGF.5. The method of claim 1 , wherein the human fibroblasts are cultured for 10-15 days.6. The method of claim 1 , further comprising the steps of:forming spheres by subculturing and then suspension culturing the human fibroblasts; andadherent culturing the formed spheres and then suspension culturing the adherent cultured spheres.7. The method of claim 6 , wherein the suspension culture and the adherent culture are each performed for 7-10 ...

Подробнее
Номер записи: 10
10-01-2019 дата публикации

Method for Culturing Limbal Stem Cells by Using Amniotic Membrane Slide Scaffold

Номер: US20190010454A1
Автор: CHUNG So-Hyang, Lee Hyun Jung, SEO Kyung Yul
Принадлежит:

The present invention relates to a method for culturing limbal tissues on an amniotic membrane slide scaffold, thereby enabling the proportion of limbal stem cells in a limbal tissue-derived epithelial cell sheet to be effectively increased, and the same to be cultured. According to the present invention, the proportion of limbal stem cells in in a limbal tissue-derived epithelial cell sheet can be stably and rapidly increased, and thus the success rate can be increased when in limbal tissue-derived epithelial cell sheets are transplanted into a patient with limbal stem cell deficiency. 1. A method for culturing limbal stem cells , comprising:covering a slide glass scaffold with an epithelial cell-removed amniotic membrane for fixation; andculturing limbal tissue on the fixed amniotic membrane.2. The method according to claim 1 , wherein each of the width and length of the amniotic membrane is 28 to 35 mm.3. The method according to claim 1 , wherein epithelial cells of the amniotic membrane are removed using 4 to 6 M urea.4. The method according to claim 1 , wherein each of the width and length of the slide glass is 18 to 28 mm.5. The method according to claim 1 , wherein the limbal tissue is cultured in DMEM/F12(1:1) supplemented with human serum claim 1 , an epithelial cell growth factor (EGF) claim 1 , dimethyl sulfoxide (DMSO) claim 1 , insulin transferrin selenium (ITS) and 0-phosphoethanolamine.6. The method according to claim 5 , wherein the human serum is a human albumin serum claim 5 , and added at 4 to 6% (v/v) of the entire medium.7. The method according to claim 1 , wherein the limbal tissue is cultured for 10 to 14 days.8. The method according to claim 7 , wherein claim 7 , when the limbal tissue is grown to 85 to 95% of the area of the scaffold claim 7 , the limbal tissue is classified as a transplant for a patient. The present invention relates to a method for culturing limbal stem cells using an amniotic membrane slide scaffold. More particularly, ...

Подробнее
Номер записи: 11
21-01-2021 дата публикации

CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION

Номер: US20210017488A1
Автор: MEIER Steven J., VARMA Sharat, VIJAYASANKARAN Natarajan, Yang Yi
Принадлежит: Genentech, Inc.

Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided. 1. A method of culturing a cell comprising a nucleic acid encoding a polypeptide , wherein the method comprises the step of contacting the cell with a cell culture medium comprising hypotaurine or an analog or precursor thereof , wherein the cell culture medium comprising the hypotaurine or an analog of precursor thereof reduces the color intensity of a composition comprising the polypeptide produced by the cell as compared to the color intensity of a composition comprising the polypeptide produced by the cell cultured in a cell culture medium that does not comprise the hypotaurine or an analog or precursor thereof.2. The method of claim 1 , wherein the cell culture medium comprising the hypotaurine or an analog or precursor thereof reduces the color intensity of a composition comprising the polypeptide produced by the cell by at least about 0.1% as compared to a composition comprising the polypeptide produced by the cell cultured in a cell culture medium that does not comprise the hypotaurine or an analog or precursor thereof.3. The method of claim 1 , wherein the cell culture medium comprising the hypotaurine or an analog or precursor thereof reduces the color intensity of a composition comprising the polypeptide produced by the cell by about 5% to about 50% as compared to a composition comprising the polypeptide produced by the cell cultured in a cell culture medium that does not comprise the hypotaurine or an analog or precursor thereof.4. The method of any one of - claim 1 , wherein the cell culture medium comprises the hypotaurine or an analog or precursor thereof at a concentration of at least about 0.0001 mM.5. The method of claim 4 , wherein the cell culture medium comprises the ...

Подробнее
Номер записи: 12
25-01-2018 дата публикации

ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS

Номер: US20180023048A1
Автор: Dorner Friedrich, Grillberger Leopold, Mundt Wolfgang, Reiter Manfred
Принадлежит:

The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes. 1. An animal protein-free cell culture medium , comprising at least one polyamine and at least one protein hydrolysate derived from the group consisting of plants and yeast , wherein the polyamine is present in the culture medium in a concentration ranging from about 0.5 to about 30 mg/L.2. The animal protein-free cell culture medium according to claim 1 , wherein the polyamine is selected from the group consisting of cadaverine claim 1 , putrescine claim 1 , spermidine claim 1 , spermine claim 1 , agmatine claim 1 , ornithine claim 1 , and a combination thereof.3. The animal protein-free cell culture medium according to claim 1 , wherein the polyamine is putrescine in a concentration ranging from about 0.5 to about 10 mg/L claim 1 , and the protein hydrolysate is soy hydrolysate in a concentration ranging from about 0.05% (w/v) to about 5% (w/v)4. The animal protein-free cell culture medium according to claim 1 , wherein the polyamine originates from a source other than a protein hydrolysate.5. The animal protein-free cell culture medium according to claim 1 , wherein the polyamine is present in the culture medium in a concentration ranging from about 0.5 to about 10 mg/L.6. The animal protein-free cell culture medium according to claim 1 , wherein the polyamine is present in the culture medium in a concentration ranging from about 2 to about 8 mg/L.7. The animal protein-free cell culture medium according to claim 1 , wherein the protein hydrolysate is present in ...

Подробнее
Номер записи: 13
04-02-2016 дата публикации

THEOBROMINE COMPOSITIONS USEFUL FOR INCREASING FETAL WEIGHT GAIN AND ENHANCING BONE PROPERTIES

Номер: US20160030434A1
Автор: NAKAMOTO Tetsuo, SADEGHPOUR Arman
Принадлежит:

Compositions and methods for culturing cells with theobromine are provided, as well as cells derived thereby. Theobromine compositions for enhancing bone formation, increasing bone density, increasing interconnections of internal bone, increasing bone mass, treating cartilage and/or bone defects, increasing fetal birth weight, preventing tooth decay, remineralizing a tooth surface, treating dentine hypersensitivity, and application to a bone site to promote new bone growth at the site are also provided. 1. An isolated cell in a culture medium , said culture medium comprising theobromine , a salt or double salt of theobromine , or a co-crystal comprising theobromine.2. The isolated cell of claim 1 , wherein said isolated cell is a mammalian cell.3. The isolated cell of claim 1 , wherein said isolated cell is a stem cell.4. The stem cell of claim 3 , wherein said stem cell is a mesenchymal stem cell.5. The cell of claim 1 , wherein said theobromine claim 1 , salt or double salt of theobromine claim 1 , or co-crystal comprising theobromine is from 1 to 300 μM.6. A method of culturing a cell claim 1 , the method comprising:culturing said cell in a culture medium, wherein said culture medium comprises theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine.7. The method of claim 6 , wherein said cell is a mammalian cell.8. The method of claim 6 , wherein said cell is a stem cell.9. The method of claim 8 , wherein said stem cell is a mesenchymal stem cell.10. The method of claim 6 , wherein said theobromine is from 1 to 300 μM.11. A culture medium comprising theobromine claim 6 , a salt or double salt of theobromine claim 6 , or a co-crystal comprising theobromine.12. The culture medium of claim 11 , wherein said theobromine claim 11 , salt or double salt of theobromine claim 11 , or co-crystal comprising theobromine is from 1 to 300 μM.13. The culture medium of claim 11 , wherein said theobromine claim 11 , salt or double salt of ...

Подробнее
Номер записи: 14
02-02-2017 дата публикации

CANINE AUTOLOGOUS IMMUNOTHERAPY USING DENDRITIC CELL INDUCED CANCER KILLING IMMUNOCYTES

Номер: US20170029775A1
Автор: Ichim Thomas, Koos David
Принадлежит:

Described are compositions of matter, protocols, and treatment means for induction of immune mediated killing in dogs suffering from cancer. The invention provides means of extracting peripheral blood from a canine patient, expanding immunocytes capable of killing cancer cells in vitro, and re-administering said immunocytes into a patient in need of therapy. In one embodiment, immunocytes expanded are T cells possessing tumor cytotoxic activity induced by stimulation of NKG2D. 1. A method of generating a canine immunocyte possessing cytotoxicity against cancer cells comprising: a) obtaining canine blood; b) isolating peripheral blood mononuclear cells from the canine blood; c) isolating monocytic cells from said canine blood; d) isolating CD355+ cells from the canine blood; e) inducing said monocytic cells to differentiate into dendritic cells; f) co-culturing said dendritic cells with said CD355+ expressing cells.2. The method of claim 1 , wherein said peripheral blood mononuclear cells are isolated from said canine blood by a density gradient.3. The method of claim 1 , wherein said peripheral blood mononuclear cells are isolated from said canine blood wherein said density gradient is percoll.4. The method of claim 1 , wherein said peripheral blood mononuclear cells are isolated from said canine blood wherein said density gradient is ficoll.5. The method of claim 1 , wherein said monocytic cells are collected by plastic adherence.6. The method of claim 1 , wherein said monocytic cells are collected by magnetic activated cell separation for CD14.7. The method of claim 1 , wherein said monocytic cells are collected by fluorescent activated cell separation for CD14.8. The method of claim 1 , wherein said cells expressing CD355 are collected by a means selected from a group comprising of: a) magnetic activated cell separation; b) fluorescent activated cell separation; and c) panning.9. The method of claim 1 , wherein said monocytic cells are differentiated into ...

Подробнее
Номер записи: 15
12-02-2015 дата публикации

CELL LINE ADAPTED TO A PROTEIN-FREE AND LIPID-FREE MEDIUM, A METHOD FOR PRODUCING THE CELL LINE, AND A MEDIUM FOR THE CELL LINE

Номер: US20150044769A1
Автор: Sasaki Tetsuji
Принадлежит: Kyokuto Pharmaceutical Industrial Co., Ltd.

A cell of a cell line adapted to a protein-free and lipid-free medium, which is derived from CHO cells, can be stably used for production of recombinant proteins and can proliferate in a suspended state in a protein-free and lipid-free medium containing no exogenous growth factors. A method for adapting CHO cells by using a protein-free and lipid-free medium and a medium used for the method. 1. A cell of a cell line derived from Chinese Hamster Ovary (CHO) cells , the cell line being adapted to a protein-free and lipid-free medium , characterized in that the cell can proliferate in a suspended state in a protein-free and lipid-free medium comprising no exogenous growth factors.2. The cell as described in claim 1 , wherein the cell line has been deposited under Accession number NITE P-01641.3. A protein-free and lipid-free medium for culturing cells of an established cell line derived from CHO cells claim 1 , the cell line being adapted to a protein-free and lipid-free medium claim 1 , characterized by comprising putrescine claim 1 , thymidine claim 1 , hypoxanthine claim 1 , and monoethanolamine in a DMEM medium that has been modified so as to contain glucose in an amount of 3 to 5 times of the usual amount claim 1 , and by comprising no exogenous growth factors.4. The protein-free and lipid-free medium as described in claim 3 , which comprises 2000 to 5000 mg/L of glucose claim 3 , 0.001 to 2 mg/L of putrescine claim 3 , 0.01 to 1 mg/L of thymidine claim 3 , 0.1 to 10 mg/L of hypoxanthine claim 3 , and 0.1 to 5 mg/L of monoethanolamine.5. The protein-free and lipid-free medium as described in claim 3 , which further comprises 1 to 20 mg/L of insulin.6. A composition for producing the medium as described in claim 3 , which comprises claim 3 , in addition to the composition of the DMEM medium claim 3 , components of: 2000 to 5000 mg/L of glucose claim 3 , 0.001 to 2 mg/L of putrescine claim 3 , 0.01 to 1 mg/L of thymidine claim 3 , 0.1 to 10 mg/L of hypoxanthine ...

Подробнее
Номер записи: 16
06-02-2020 дата публикации

CELL CULTURE MEDIA

Номер: US20200040301A1
Автор: Ince Tan
Принадлежит:

A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (ATRA) and vitamin C; zinc, magnesium, and copper; an agent that increases intracellular cAMP; epidermal growth factor (EGF); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin D, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors. 121-. (canceled)22. A cell culture medium comprising:(a) adenosine triphosphate; (b) a carrier protein; (c) cholesterol, linoleic acid, and lipoic acid; (d) glutathione; (e) at least one nucleotide salvage pathway precursor base; (f) phosphoethanolamine; (g) selenium; (h) transferrin; (i) triiodothyronine; (j) all-trans-retinoic acid (ATRA) and vitamin C; (k) zinc, magnesium, and copper; (l) an agent that increases intracellular cAMP; (m) epidermal growth factor (EGF); (n) hydrocortisone; (o) insulin; and (p) charcoal-stripped fetal bovine serum; andwherein said cell culture medium is substantially free of estrogenic hormones and estrogenic ligands.23. The cell culture medium of claim 22 , wherein said culture medium is substantially free of vitamin D.24. The cell culture medium of claim 23 , wherein said culture medium is substantially free of androgenic hormones and androgenic ligands.25. The cell culture medium of claim 22 , wherein said culture medium is substantially free of androgenic hormones and androgenic ligands.26. A method of culturing breast cancer cells comprising claim 22 ,obtaining a sample of breast cancer cells from cancerous breast tissue,{'claim-ref': {'@idref': 'CLM-00022', 'claim 22'}, 'adding an amount of the cell culture medium of to the sample of breast cancer cells, and'}{'claim- ...

Подробнее
Номер записи: 17
18-02-2016 дата публикации

CELL SHEET CONSTRUCT FOR NEUROVASCULAR RECONSTRUCTION AND MANUFACTURE THEREOF

Номер: US20160045641A1
Автор: CHOU Chung-Hsing, HUENG Dueng-Yuan, TSAI Tsung-Neng
Принадлежит:

The invention relates to a cell sheet construct for neurovascular reconstruction. The cell sheet construct has a vascular endothelial cell layer and a neural stem cell layer, and the two layers are physically in direct contact with each other, where the vascular endothelial cell layer forms branching vasculatures, and the neural stem cell layer differentiates into neurons. The invention also relates to a method for manufacturing the cell sheet construct, having the following steps: culturing vascular endothelial cells on a substrate to form a vascular endothelial cell layer, seeding neural stem cells on the vascular endothelial cell layer to make the neural stem cells be physically in direct contact with the vascular endothelial cell layer, and culturing the neural stem cells and the vascular endothelial cell layer to differentiate into neurons and branching vasculatures to form a cell sheet construct. 1. A cell sheet construct for neurovascular reconstruction , comprising:a vascular endothelial cell layer having vascular endothelial cells; anda neural stem cell layer having neural stem cells;wherein the vascular endothelial cell layer is physically in direct contact with the neural stem cell layer, the vascular endothelial cell layer differentiates into branching vasculatures, and the neural stem cell layer differentiates into neurons.2. The cell sheet construct of claim 1 , wherein the vascular endothelial cells are human cerebral microvascular endothelial cells.3. The cell sheet construct of claim 1 , wherein the neural stem cells are human cerebral neural stem cells.4. The cell sheet construct of claim 1 , wherein the vascular endothelial cell layer further comprises extracellular matrix claim 1 , and the extracellular matrix as well as the vascular endothelial cells are used as a carrier.5. The cell sheet construct of claim 4 , wherein the extracellular matrix comprises polypeptide claim 4 , collagen claim 4 , polysaccharide claim 4 , hyaluronic acid claim 4 , ...

Подробнее
Номер записи: 18
16-02-2017 дата публикации

NOCICEPTOR-LIKE CELLS DIFFERENTIATED FROM HUMAN NEURAL PROGENITORS AND USES THEREOF

Номер: US20170045499A1
Автор: Guo Xiufang, Hickman James J.
Принадлежит:

Disclosed herein are methods of differentiating human neural progenitor cells to nociceptor-like cells. Also disclosed are methods of making an innervated skin-like construct using nociceptor-like cells differentiated from human neural progenitor cells. Also disclosed are engineered constructs for screening potentially therapeutic compounds that include a skin-like construct and nociceptor-like cells differentiated from human neural progenitor cells. Also disclosed is a method of screening potential therapies. 1. A method of differentiating human neural progenitor cells to nociceptor-like cells , comprising:a) exposing human neural progenitor cells to a first serum-free initiation medium for a first time period; andb) exposing the human neural progenitor cells to a second serum-free initiation medium for a second time period; andc) exposing the human neural progenitor cells to a serum-free differentiation medium during a third time period to cause at least a portion of the human neural progenitor cells to differentiate into nociceptor-like cells;wherein the nociceptor-like cells possess at least one nociceptor-like property.2. The method of claim 1 , wherein the first serum-free initiation medium comprises KSR base medium claim 1 , SB43152 claim 1 , and LDN-193189.3. The method of claim 2 , wherein the concentration of SB43152 in the first serum-free initiation medium is from 1-100 μM claim 2 , and wherein the concentration of LDN-193189 in the first-serum free initiation medium is from 10-1000 nM.4. The method of claim 3 , wherein the SB43152 concentration in the first-serum free initiation medium is about 10 μM claim 3 , and wherein the concentration of LDN-193189 in the first-serum free initiation medium is about 100 nM.5. The method of claim 1 , wherein the first time period is from 1-5 days.6. The method of claim 5 , wherein the first time period is about 2 days.7. The method of claim 1 , wherein the second serum-free initiation medium comprises SB43152 claim 1 ...

Подробнее
Номер записи: 19
22-02-2018 дата публикации

Chelated iron-containing culture medium for neural stem cells

Номер: US20180051250A1
Автор: Akihiro ARAKAWA, Sho SENDA, Takuya Matsumoto, Tsuyoshi Kobayashi
Принадлежит: Ajinomoto Co Inc

Culture media, which contain chelated iron, promote cell proliferation of neural stem cells and/or neural progenitor cells while maintaining undifferentiated state and multipotency.

Подробнее
Номер записи: 20
02-03-2017 дата публикации

CELL CULTURE MEDIA

Номер: US20170058259A1
Автор: Ince Tan A.
Принадлежит:

A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (ATRA) and vitamin C; zinc, magnesium, and copper; an agent that increases intracellular cAMP; epidermal growth factor (EGF); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin D, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors. 1. A cell culture medium comprising:(a) adenosine triphosphate;(b) a carrier protein;(c) cholesterol, linoleic acid, and lipoic acid;(d) glutathione;(e) at least one nucleotide salvage pathway precursor base,(f) phosphoethanolamine;(g) selenium;(h) transferrin;(i) triiodothyronine;(j) all-trans-retinoic acid (ATRA) and vitamin C;(k) zinc, magnesium, and copper;(l) an agent that increases intracellular cAMP;(m) epidermal growth factor (EGF);(n) hydrocortisone;(o) insulin; and(p) charcoal stripped fetal bovine serum;wherein said cell culture medium is substantially free of vitamin D.2. The cell culture medium as recited in wherein said medium is substantially free of any variety of vitamin D and vitamin D precursors claim 1 , derivatives claim 1 , or intermediates.3. The cell culture medium as recited in wherein said medium is substantially free of vitamin D2 claim 2 , vitamin D3 claim 2 , calciferol claim 2 , calcitriol claim 2 , drisdol claim 2 , 7-dehydrocholesterol claim 2 , cholecalciferol claim 2 , 25-hydroxyvitamin D3 claim 2 , and 1 claim 2 ,25-dihydroxyvitamin D3.4. The cell culture medium of configured to support proliferation of breast cancer cells for at least about 15 population doublings.5. A cell culture medium comprising:(a) adenosine triphosphate;(b) a carrier protein;(c) cholesterol, ...

Подробнее
Номер записи: 21
22-05-2014 дата публикации

Thermoplastic resin composition for impact absorbing member and method for producing same

Номер: US20140142219A1
Автор: Hideo Matsuoka, Masaru Akita, Shigemitsu Suzuki, Shingo Nishida, Yasufumi Morita
Принадлежит: TORAY INDUSTRIES INC

A thermoplastic resin composition includes 1 to 200 parts by weight of an inorganic filler (C) blended with 50 to 80 parts by weight of a thermoplastic resin (A) and 20 to 50 parts by weight of a rubbery polymer having a reactive functional group (B) which together account for 100 parts by weight; wherein the thermoplastic resin (A) and the rubbery polymer having a reactive functional group (B) form a continuous phase and a dispersed phase, respectively, while the inorganic filler (C) is dispersed in the continuous phase and/or the dispersed phase; and the dispersed phase of the rubbery polymer contains fine particles with a diameter of 1 to 100 nm of a compound resulting from a reaction between the thermoplastic resin (A) and the rubbery polymer; and an area occupied by the fine particles account for 10% or more of the dispersed phase.

Подробнее
Номер записи: 22
10-03-2016 дата публикации

OLIGOPEPTIDE-FREE CELL CULTURE MEDIA

Номер: US20160068587A1
Автор: Grillberger Leopold, Mitterer Artur, Mundt Wolfgang, Reiter Manfred
Принадлежит:

The present invention relates to oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine and to methods for cultivating cells in said oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine. The invention also relates to methods for expressing at least one protein in a medium comprising at least 0.5 mg/L of a polyamine and to methods for producing at least one virus in a medium comprising at least 0.5 mg/L of a polyamine. 1. A method for expressing a coagulation factor VIII protein , comprising the steps of:(a) providing a culture of CHO cells;(b) introducing at least one nucleic acid sequence comprising a sequence coding for the coagulation factor VIII protein into the cells;(c) selecting the cells carrying the nucleic acid sequence; and(d) expressing the coagulation factor VIII protein in an oligopeptide-free chemically defined medium comprising DMEM:HAM's F12 (1:1) basal medium, putrescine at a concentration of at least 1 mg/L, and Fe(II) and Cu(II) at a level greater than the amount in basal DMEM:HAM's F12 (1:1), wherein the cells are cultivated by chemostat cultivation.2. The method of claim 1 , wherein the putrescine is present in the culture medium at a concentration ranging from 1 to 20 mg/L.3. The method of claim 1 , wherein the chemically defined medium is supplemented with L-glutamine claim 1 , ascorbic acid claim 1 , ethanolamine claim 1 , sodium selenite claim 1 , and a non-ionic surfactant. This application is a continuation of U.S. patent application Ser. No. 13/035,696 filed Feb. 25, 2011, which is a continuation of U.S. patent application Ser. No. 11/649,694 filed Jan. 3, 2007, which claims benefit of U.S. provisional application Ser. No. 60/756,419 filed Jan. 4, 2006, which applications are herein incorporated by reference.The present invention relates to oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine and to methods for cultivating cells in said oligopeptide-free ...

Подробнее
Номер записи: 23
10-03-2016 дата публикации

METHOD FOR CULTURING SKELETAL MUSCLE FOR TISSUE ENGINEERING

Номер: US20160068812A1
Автор: Das Mainak, Hickman James J., Rumsey John W.
Принадлежит:

The invention provides a nutrient medium composition and associated methods for lengthening the useful life of a culture of muscle cells. Disclosed is a method of culturing mammalian muscle cells, including preparing one or more carriers coated with a covalently bonded monolayer of trimethoxy-silylpropyl-diethylenetriamine (DETA); verifying DETA monolayer formation by one or more associated optical parameters; suspending isolated fetal rat skeletal muscle cells in serum-free medium according to medium composition 1; plating the suspended cells onto the prepared carriers at a predetermined density; leaving the carriers undisturbed for cells to adhere to the DETA monolayer; covering the carriers with a mixture of medium 1 and medium 2; and incubating. A cell nutrient medium composition includes Neurobasal, an antibiotic-antimycotic composition, cholesterol, human TNF-alpha, PDGF BB, vasoactive intestinal peptides, insulin-like growth factor 1, NAP, r-Apolipoprotein E2, purified mouse Laminin, beta amyloid, human tenascin-C protein, rr-Sonic hedgehog Shh N-terminal, and rr-Agrin C terminal. 122-. (canceled)23. A method of maintaining a muscle cell culture , the method comprising:maintaining the muscle cell culture in a serum-free medium comprising NBActiv4.24. The method of claim 23 , wherein the muscle cell culture is maintained in a serum-free medium comprising NBActiv4 for at least 30 days.25. The method of claim 24 , wherein the muscle cell culture is maintained in a serum-free medium comprising NBActiv4 for at least 50 days.26. The method of claim 23 , further comprising plating the muscle cell culture onto a non-biological growth substrate prior to maintaining the muscle cell culture in a serum-free medium comprising NBActiv4.27. The method of claim 26 , wherein the non-biological growth substrate comprises a silane molecule.28. The method of claim 27 , wherein the non-biological growth substrate is DETA.29. The method of claim 23 , further comprising plating the ...

Подробнее
Номер записи: 24
10-03-2016 дата публикации

Methods of cell culture

Номер: US20160068881A1
Автор: Holly Prentice
Принадлежит: Momenta Pharmaceuticals Inc

Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described.

Подробнее
Номер записи: 25
27-02-2020 дата публикации

Use of n-butylidenephthalide in dopaminergic progenitor cell transplantation

Номер: US20200063098A1
Автор: Chi-Hsuan CHUANG, Chia-Hsin Lee, Chia-Yu Chang, Ching-I SHEN, Lin-Hsiang CHUANG, Ming-Hsi Chuang, Po-Cheng Lin, Shinn-Zong Lin, Yi-Chun Lin
Принадлежит: ULTRA-MICRORIGIN BIOMEDICAL TECHNOLOGY Co Ltd

Uses of n-butylidenephthalide (BP) in dopaminergic progenitor cell transplantation are provided, wherein the uses include using BP to enhance the therapeutic effect of dopaminergic progenitor cell transplantation, and using a combination of BP and BP-treated dopaminergic progenitor cells in dopaminergic progenitor cell transplantation. The uses especially relate to using BP to enhance the therapeutic effect of dopaminergic progenitor cell transplantation on Parkinson's disease.

Подробнее
Номер записи: 26
11-03-2021 дата публикации

Cell Culture Medium for Eukaryotic Cells

Номер: US20210071135A1
Автор: Chen John, Golden Nathaniel, Loney Theodore, Scott Carolyn, Xue Wei
Принадлежит:

Cell culture media are provided herein as are methods of using the media for cell culture and protein production from cells. 1. A cell culture medium for eukaryotic cells expressing Aflibercept , comprising:a basal medium or a feed medium; and5-methylthioadenosine or nicotinamide.2. The cell culture medium of claim 1 , wherein a concentration of 5-methylthioadenosine in the cell culture medium is at least about 10 nM.3. The cell culture medium of claim 1 , wherein a concentration of the nicotinamide in the cell culture medium is at least about 50 nM.4. The cell culture medium of further comprising one or more acids selected from lactic acid claim 1 , phenyl lactic acid claim 1 , indolelactic acid claim 1 , succinic acid claim 1 , alpha-hydroxyisovaleric acid claim 1 , alpha-hydroxyisocaproic acid claim 1 , 2-(4-hydroxyphenyl)lactic acid claim 1 , or 2-hydroxy-3-methylvaleric acid claim 1 , salts of these acids claim 1 , esters of these acids and combinations thereof.5. The cell culture medium of claim 2 , wherein a titer of the Aflibercept produced in the cell culture medium is at least about 2% greater than another cell culture medium that does not have at least about 10 nM 5-methylthioadenosine.6. The cell culture medium of claim 3 , wherein a titer of the Aflibercept produced in the cell culture medium is at least about 2% greater than another cell culture medium that does not have at least about 50 nM nicotinamide.7. The cell culture medium of claim 1 , wherein the 5-methylthioadenosine or the nicotinamide can be in the form of its salts or esters.8. The cell culture medium of claim 1 , wherein pH of the medium is maintained in the range of about 6.5 to about 8.9. The cell culture medium of claim 1 , wherein the medium does not have a protein derived from an animal.10. The cell culture medium of claim 1 , wherein the medium is a serum-free medium.11. The cell culture medium of claim 1 , wherein the medium is a chemically-defined medium.1231.-. (canceled)32. A ...

Подробнее
Номер записи: 27
12-03-2015 дата публикации

DIFFERENTIATED HUMAN LIVER CELL CULTURES AND THEIR USE IN BIOARTIFICIAL LIVER SYSTEMS

Номер: US20150073389A1
Автор: Chamuleau Robert Antoine François Marie, Hoekstra Ruurdtje, Nibourg Gerardus Adrianus Antonius
Принадлежит: ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM

Human hepatocyte cell cultures and their use in bioreactors and bioartificial liver (BAL) systems are provided. The cells have constitutive liver-specific metabolic activity resembling that of freshly isolated human hepatocytes. The hepatocyte cells and BAL systems can be used to treat patients suffering from acute liver failure, end-stage liver disease, or acute-on-chronic liver disease. 1. A cell culture comprising differentiated cells from a human hepatocyte cell line in a suitable culture medium , wherein said differentiated cells have constitutive liver-specific metabolic activity , the cell culture being obtained by a process comprising:selecting a human hepatocyte cell line;a phase of cell proliferation comprising culturing cells of said human hepatocyte cell line in a suitable culture medium, preferably comprising serum, hormones, growth-factors and antibiotics;loading viable cells to an amount of at least 5% of normal liver mass in a bioreactor comprising a three dimensional support matrix, and allowing the cells to attach to said matrix;an expansion or proliferation phase comprising culturing the cells loaded in the bioreactor in a suitable culture medium, preferably comprising serum, hormones, growth-factors and antibiotics, to achieve at least one cell population doubling; anda phase of cell differentiation comprising culturing the cells in a culture medium comprising serum, hormones, growth factors and antibiotics.2. The cell culture according to claim 1 , wherein the cell differentiation phase lasts at least 7 days.3. The cell culture according to claim 1 , wherein the three dimensional support matrix comprises a porous sheet or mat claim 1 , a fiber network matrix claim 1 , an open-pore foam claim 1 , or a semi-solid material.4. The cell culture according to claim 1 , wherein said human hepatocyte cell line is HepaRG claim 1 , deposited at the Collection Nationale de Cultures de Microorganismes claim 1 , Institut Pasteur claim 1 , Accession No. 1-2652 ...

Подробнее
Номер записи: 28
07-03-2019 дата публикации

COMPOSITIONS AND METHODS FOR CULTURING CELLS FROM NORMAL HUMAN TUBO-OVARIAN EPITHELIUM AND HUMAN TUBO-OVARIAN TUMORS

Номер: US20190071634A1
Автор: Ince Tan A.
Принадлежит:

Described herein are cell culture media, kits and methods for preparing cell culture media, and methods for culturing cells, for example, cells of the female reproductive tract, and tumor cells. 1. A cell culture medium , or a kit for preparing a cell culture medium , comprising:(a) adenosine triphosphate;(b) a carrier protein;(c) cholesterol, linoleic acid, and lipoic acid;(d) glutathione;(e) a nucleotide salvage pathway precursor base selected from hypoxanthine, xanthine, adenine, guanine and thymidine;(f) phosphoethanolamine;(g) selenium;(h) transferrin;(i) triiodothyronine;(j) vitamin A, vitamin C, and vitamin D;(k) Zn, Mg, and Cu;(l) an agent that increases intracellular cAMP;(m) epidermal growth factor (EGF);(n) hydrocortisone;(o) insulin; and(p) serum.2. The cell culture medium of claim 1 , further comprising one or more of:(a) adenosine monophosphate;(b) vitamin E; or(c) at least one of vitamin K3, niacin, or niacinamide.3. (canceled)4. The cell culture medium of claim 1 , wherein the carrier protein is albumin.57-. (canceled)8. The cell culture medium of claim 1 , wherein the agent that increases intracellular cAMP is cholera toxin.924-. (canceled)25. The cell culture medium of claim 1 , further comprising an estrogen.2627-. (canceled)28. The cell culture medium of claim 25 , wherein the estrogen is 17-beta-estradiol.29. The cell culture medium of claim 1 , wherein the medium is substantially free of estrogen.3036-. (canceled)37. The cell culture medium of claim 1 , wherein the medium supports proliferation of ovarian tumor cells for at least about 15 population doublings (PD) in vitro.38. The cell culture medium of claim 1 , wherein the medium supports proliferation of ovarian cells and/or fallopian tube cells for at least about 15 population doublings (PD) in vitro.39. A kit for preparing the cell culture medium of claim 1 , comprising a first one or more containers comprising components (a)-(k) and a second one or more containers comprising components (l ...

Подробнее
Номер записи: 29
07-03-2019 дата публикации

EFFICIENT DIFFERENTIATION OF HUMAN STEM CELLS TO DEFINITIVE ENDODERM

Номер: US20190071645A1
Автор: Mora Sergio
Принадлежит:

The present disclosure provides a medium for cells, such as human stem cells including human induced pluripotent stem cells (iPScs) which medium enhances the formation of definitive endoderm (DE) which in turn can be subsequently directed and differentiated into mature cell types, e.g., pancreas insulin producing cells. 1. A cell medium composition , comprising:a) one or more base tissue culture media;an amount of glutamine or an analog thereof;an amount of one or more lipids;an amount of one or more non-essential amino acids;an amount of one or more thiols;an amount of one or more of insulin, transferrin or selenium; andan amount of polyvinylalcohol; orb) one or more base tissue culture media;an amount of glutamine or an analog thereof;an amount of one or more non-essential amino acids; and optionally an amount of an inhibitor of glycogen synthase kinase 3 or an amount of an inhibitor of AMP activated protein kinase; orc) one or more base tissue culture media;an amount of glutamine or an analog thereof;an amount of selenium; and optionally an amount of an inhibitor of glycogen synthase kinase 3 or an amount of an inhibitor of AMP activated protein kinase.2. The composition of further comprising an amount of Activin claim 1 , comprising an amount of an activator of WNT signaling or an inhibitor of glycogen synthase kinase 3.3. The composition of wherein the amount of Activin is about 50 ng/mL to about 150 ng/mL.4. The composition of wherein the activator of WNT signaling or the inhibitor of glycogen synthase kinase 3 comprises CHIR99021.5. The composition of wherein the amount of CHIR99021 is about 1 μM to about 3 μM.6. The composition of wherein the amount of glutamine or the analog thereof comprises about 0.1% vol/vol to about 5% vol/vol.7. The composition of wherein the amount of the one or more lipids comprises about 0.1% vol/vol to about 5% vol/vol.8. The composition of wherein the thiol comprises monothioglycerol.9. The composition of wherein the amount of the ...

Подробнее
Номер записи: 30
24-03-2022 дата публикации

METHOD OF PRODUCING ENTERIC NEURONS AND USES THEREOF

Номер: US20220090010A1
Автор: Fattahi Faranak
Принадлежит:

The present disclosure relates generally to methods and systems of producing enteric neurons from pluripotent stem cells under fully defined conditions. The enteric neural crest cells and enteric neurons produced by the disclosed methods find applications as models of the enteric nervous system, tools for high-throughput screening of potential therapeutics for treatment of enteric neuropathies, and in regenerative medicine. 1. A method of culturing pluripotent stem cells comprising:(a) diluting pluripotent stem cells with a culture medium to obtain a pluripotent stem cell mixture;(b) centrifuging the pluripotent stem cell mixture to obtain a pellet and a supernatant;(c) removing the supernatant from the pellet;(d) adding culture medium to the pellet and resuspending the pluripotent stem cells in the culture medium to obtain resuspended pluripotent stem cells;(e) plating the resuspended pluripotent stem cells on a hydrogel disposed within a culture vessel to obtain plated pluripotent stem cells; and(f) incubating the plated pluripotent stem cells to a confluency of about 80%.2. The method of claim 1 , wherein claim 1 , in step (a) or (d) claim 1 , the culture medium is removed and replaced with fresh culture medium about every 2 days.3. (canceled)4. The method of claim 1 , wherein the pluripotent stem cells are human pluripotent stem cells.5. The method of claim 1 , wherein the pluripotent stem cells are selected from the group consisting of human ES cell line H9 (WA-09) claim 1 , human ES cell line UCSF4 claim 1 , human iPS cell line WTC11 claim 1 , and combinations thereof.6. The method of claim 1 , wherein the hydrogel comprises a solubilized basement membrane preparation extracted from Engelbreth-Holm-Swarm mouse sarcoma claim 1 , the solubilized basement membrane preparation comprising a laminin claim 1 , a collagen IV claim 1 , a heparin sulfate proteoglycan claim 1 , and entactin/nidogen.7. The method of claim 1 , wherein the hydrogel comprises vitronectin.8. ...

Подробнее
Номер записи: 31
16-03-2017 дата публикации

COMPOSITIONS OF ADULT DISC STEM CELLS AND METHODS FOR THE TREATMENT OF DEGENERATIVE DISC DISEASE

Номер: US20170073640A1
Автор: Duntsch Christopher, Ignatova Tatyana, Kukekov Valery
Принадлежит:

This invention provides an isolated disc stem cell population, compositions, and methods of obtaining and growing the same. Moreover, this invention provides an isolated discosphere, compositions, and methods of obtaining and growing the same. An artificial disc containing the cells of the present invention is provided together with methods of making the same. This invention also provides a method of treating a subject having a herniated disc utilizing the cells and methods of the invention. 1. An isolated discosphere , wherein said discosphere is a free-floating in vitro structure comprising disc stem cells , disc progenitor cells , or a combination thereof.2. The isolated discosphere of claim 1 , wherein said discosphere comprises cells originating from a single disc stem cell.3. A composition comprising the discosphere of .4. The composition of claim 4 , wherein said composition further comprises a media.5. The composition of claim 5 , wherein said media is a serum free media.6. The composition of claim 5 , wherein said media further comprises FGF2 claim 5 , EGF claim 5 , SCF claim 5 , IL-6 claim 5 , IL-2 claim 5 , TGF-β claim 5 , LIF claim 5 , or a combination thereof.7. The composition of claim 5 , wherein said media additionally comprises insulin claim 5 , progesterone claim 5 , putrescine claim 5 , transferrin claim 5 , sodium selenite claim 5 , or a combination thereof.8. A method of producing the discosphere of claim 1 , comprising the step of growing a culture of nucleus pulposus cells in a serum free media comprising methylcellulose claim 1 , thereby producing a discosphere.9. The method of claim 9 , wherein said nucleus pulposus cells are human nucleus pulposus cells.10. The method of claim 9 , wherein said media further comprises FGF2 claim 9 , EGF claim 9 , SCF claim 9 , IL-6 claim 9 , IL-2 claim 9 , TGF-β claim 9 , LIF claim 9 , or a combination thereof.11. The method of claim 9 , wherein said media additionally comprises insulin claim 9 , ...

Подробнее
Номер записи: 32
05-03-2020 дата публикации

DECREASING ORNITHINE METABOLISM TO DECREASE THE HIGH MANNOSE GLYCOFORM CONTENT OF RECOMBINANT PROTEINS

Номер: US20200071738A1
Автор: Barkhordarian Hedieh, BONDARENKO PAVEL, HUANG, Jr. Chung, Kang Sohye, Zhang Zhongqi
Принадлежит: Amgen Inc.

The present invention relates to a method for manipulating the high mannose glycoform content of recombinant glycoproteins by regulating ornithine metabolism during cell culture. 156.-. (canceled)57. A method of increasing high mannose glycoform content of a recombinant protein comprising culturing a host cell expressing the recombinant protein in a cell culture comprising one selected from the group consisting of ornithine , arginine , an ornithine aminotransferase inhibitor , a nitric oxide synthase inhibitor , an ornithine decarboxylase inhibitor , and an arginine decarboxylase inhibitor , wherein ornithine production in the host cell is increased when compared to the host cell expressing the recombinant protein is cultured in a cell culture lacking one selected from the group consisting of ornithine , arginine , an ornithine aminotransferase inhibitor , a nitric oxide synthase inhibitor , ornithine decarboxylase inhibitor , and an arginine decarboxylase inhibitor , andthe recombinant protein has an increased high mannose glycoform content than when the recombinant protein is expressed in the cell culture lacking one selected from the group consisting of ornithine, arginine, an ornithine aminotransferase inhibitor, a nitric oxide synthase inhibitor, ornithine decarboxylase inhibitor, and an arginine decarboxylase inhibitor.58. The method of claim 57 , whereinthe ornithine aminotransferase inhibitor is 5-fluoromethylornithine;{'sup': 'G', 'the nitric oxide synthase inhibitor is selected from the group consisting of 2-ethyl-2-thiopseudourea and N-Nitro-L-arginine and L-monomethyl-L-arginine; or'}the arginine decarboxylase inhibitor is asymmetric dimethyl-arginine.59. The method of claim 57 , wherein ornithine accumulation in the host cell is increased by the addition of at least 0.6 mM ornithine to the cell culture.60. The method of claim 57 , wherein the concentration of ornithine is selected from the group consisting of 0.6 to 14.8 mM; 6 to 14.8 mM; 0.6 mM claim ...

Подробнее
Номер записи: 33
18-03-2021 дата публикации

AGGLOMERATED MICROBIOLOGICAL MEDIA

Номер: US20210079341A1
Автор: Liu Jie J., Xia Wensheng
Принадлежит: 3M INNOVATIVE PROPERTIES COMPANY

A method of making a flowable, dried agglomerated nutrient medium is provided. The method comprises introducing a nutrient component comprising a powdered nutrient, and an agglomeration liquid, into an agglomerator comprising a flow-through-type agglomeration chamber, wet-massing the nutrient component with the agglomeration liquid in the agglomeration chamber for a predetermined period of time to form agglomerated nutrient medium particles, and exposing the agglomerated nutrient medium particles to drying conditions for a period of time to form the dried, agglomerated nutrient medium. The nutrient component facilitates the growth of a microorganism. Compositions, articles, and kits comprising the flowable, dried agglomerated nutrient medium are also provided. 2. The method of claim 1 , wherein the agglomeration liquid comprises a solvent having a dissolved nutrient that facilitates the growth of a microorganism.3. The method of claim 1 , wherein introducing a nutrient component comprises introducing a substantially uniform mixture of two or more powdered nutrients.4. The method of claim 1 , wherein one or more powdered nutrient is selected from the group consisting of a protein claim 1 , a carbohydrate claim 1 , a salt and a mixture of any two or more of the foregoing powdered nutrients.5. The method of claim 1 , further comprising the step of subjecting the dried agglomerated nutrient medium to a process that reduces the number of viable microorganisms in the dried agglomerated nutrient medium.6. The method of wherein subjecting the dried agglomerated nutrient medium to a process that reduces the number of viable microorganisms comprises exposing the dried agglomerated nutrient medium to ionizing radiation or to ethylene oxide vapor.7. The method of claim 1 , wherein the subpopulation of the particles having a size distribution range being about 149 microns to 1000 microns is a second subpopulation claim 1 , and further comprising a step of isolating a first ...

Подробнее
Номер записи: 34
14-03-2019 дата публикации

Animal Protein-Free Media for Cultivation of Cells

Номер: US20190078051A1
Автор: Dorner Friedrich, Grillberger Leopold, Mundt Wolfgang, Reiter Manfred
Принадлежит:

The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes. 1. A method for cultivating cells , comprising the steps of:(a) providing an animal protein-free cell culture medium;(b) adding a supplement to the animal protein-free cell culture medium comprising at least one polyamine and at least one protein hydrolysate derived from the group consisting of plants and yeast, wherein the resultant concentration of the at least one polyamine in the animal protein-free cell culture medium ranges from about 0.5 to about 30 mg/L; and(c) propagating the cells in the animal protein-free cell culture medium to form a cell culture.2. The method according to claim 1 , wherein the cells are selected from the group consisting of mammalian cells claim 1 , insect cells claim 1 , avian cells claim 1 , bacterial cells claim 1 , and yeast cells.3. The method according to claim 2 , wherein the mammalian cells are CHO cells.4. The method according to claim 3 , wherein the CHO cells are propagated in suspension.5. The method according to claim 4 , wherein the cell culture is a chemostat suspension culture.6. The method according to claim 1 , wherein the cells are cultivated by a method selected from the group consisting of batch-cultivation claim 1 , feed-batch-cultivation claim 1 , perfusion cultivation claim 1 , and chemostat-cultivation.7. The method according to claim 1 , wherein the polyamine is selected from the group consisting of cadaverine claim 1 , putrescine claim 1 , spermidine claim 1 , spermine claim 1 , agmatine claim 1 , ornithine ...

Подробнее
Номер записи: 35
24-03-2016 дата публикации

ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS

Номер: US20160083689A1
Автор: Dorner Friedrich, Grillberger Leopold, Mundt Wolfgang, Reiter Manfred
Принадлежит:

The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes. 1. An animal protein-free medium cell culture medium comprising at least one polyamine and at least one protein hydrolysate , wherein the hydrolysate is derived from plants or yeast.2. The animal protein-free cell culture medium of claim 1 , wherein the polyamine is present in the culture medium in a concentration ranging from about 0.5 to about 10 mg/L.3. The animal protein-free cell culture medium of claim 1 , wherein the polyamine is cadaverine claim 1 , putrescine claim 1 , spermidine claim 1 , spermine claim 1 , agmatine claim 1 , or ornithine; or a combination thereof.4. The animal protein-free cell culture medium of claim 1 , wherein the polyamine is putrescine in a concentration ranging from about 0.5 to about 10 mg/L claim 1 , and the protein hydrolysate is soy hydrolysate in a concentration ranging from about 0.05% (w/v) to about 5% (w/v).5. The animal protein-free cell culture medium of claim 1 , wherein the polyamine originates from a source other than a protein hydrolysate.6. The animal protein-free cell culture medium of claim 1 , wherein the polyamine is present in the culture medium in a concentration ranging from about 0.5 to 30 mg/L.7. The animal protein-free cell culture medium of claim 1 , wherein the protein hydrolysate is present in the culture medium in a total concentration ranging from about 0.05% (w/v) to about 5% (w/v) for all protein hydrolysates.8. The animal protein-free cell culture medium of claim 1 , wherein the protein hydrolysate is ...

Подробнее
Номер записи: 36
31-03-2016 дата публикации

Mobilizing cells expressing a type 4 cxc chemokine receptor with 4-amino pyrimidine compounds

Номер: US20160090394A1
Автор: Chi-Feng Yen, Chi-Hsin Richard King, Ming-Chu Hsu, Ying-Huey Huang
Принадлежит: Taigen Biotechnology Co Ltd

A method of mobilizing cells expressing the type 4 CXC chemokine receptor into the peripheral circulation by contacting them with an effective amount of a compound of formula (I) shown below (each variable in the formula being defined in the Specification): The method can be used to treat cancer and myocardial infarction.

Подробнее
Номер записи: 37
19-03-2020 дата публикации

METHODS FOR DIFFERENTIATING PLURIPOTENT STEM CELLS IN DYNAMIC SUSPENSION CULTURE

Номер: US20200087622A1
Автор: Halberstadt Craig R., Kayser Stephanie, Manley Nathan C., Nair Rekha R., PARIKH Abhirath S., SHOUKAT-MUMTAZ Uzma, WHITELEY Erik Michael
Принадлежит: LINEAGE CELL THERAPEUTICS, INC.

Methods for differentiating pluripotent stem cells to neuroectoderm in dynamic suspension culture using small molecule or protein inhibitors of TGFβ/Activin/Nodal signaling and BMP signaling are provided. Also provided are methods and protocols for differentiating pluripotent stem cells such as human embryonic stem cells first to neuroectoderm, then further to glial progenitor cells, and further to oligodendrocyte progenitor cells (OPCs), and compositions obtained thereby. The methods of the present disclosure reproducibly produce neuroectoderm progenitor cells by day 7 of the differentiation process, glial progenitor cells by day 21 of the differentiation process and OPCs by day 42 of the differentiation process. 1. A method for obtaining a population of cells comprising glial progenitor cells from undifferentiated human pluripotent stem cells , the method comprising:a) obtaining a suspension culture of non-embryoid body (non-EB) aggregates of undifferentiated human pluripotent stem cells, wherein the human pluripotent stem cells remain in an undifferentiated state;b) culturing the non-EB aggregates from a) in dynamic suspension in the presence of at least one inhibitor of transforming growth factor beta (TGFβ)/Activin/Nodal signaling and at least one inhibitor of bone morphogenetic protein (BMP) signaling for a first time period, thereby inducing differentiation to neuroectoderm;c) culturing the non-EB aggregates from b) in dynamic suspension in the presence of retinoic acid and at least one agonist of Smoothened receptor for a second time period; andd) culturing the aggregates from c) in dynamic suspension in the presence of basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) for a further time period, until the cells have matured into glial progenitor cells.2. The method of claim 1 , further comprising an additional step of harvesting the non-EB aggregates from d) and plating them onto a substrate claim 1 , thereby resulting in migration of ...

Подробнее
Номер записи: 38
12-05-2022 дата публикации

Culture medium for mammalian expanded potential stem cells, composition, and methods thereof

Номер: US20220145264A1
Автор: Degong RUAN, Pengtao LIU, Xuefei Gao
Принадлежит: University of Hong Kong HKU

A culture medium is provided for establishing expanded potential stem cell (EPSC) lines for mammals. Methods are provided using the medium for the in vitro conversion and maintenance of cells, including pluripotent cells into EPSCs.

Подробнее
Номер записи: 39
16-04-2015 дата публикации

ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS

Номер: US20150104867A1
Автор: Dorner Friedrich, Grillberger Leopold, Mundt Wolfgang, Reiter Manfred
Принадлежит:

The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes. 1. A method for cultivating Chinese hamerster ovary (CHO) cells in soy hydrolysate-containing animal protein-free medium supplemented with purescine to overcome inhibitory effects on cell growth due to soy hydrolysate lot variation , said method comprising the steps of:(a) providing an animal protein-free cell culture medium comprising soy hydrolysate and putrescine, wherein the putrescine is added to said culture medium in a concentration ranging from 0.5 mg/L to 10 mg/L, and the soy hydrolysate is present in a concentration ranging from 0.05% (w/v) to 0.5% (w/v); and(b) propagating the cells in the medium to form a cell culture.2. The method according to claim 1 , wherein the cells are cultivated by a method selected from the group consisting of batch-cultivation claim 1 , feed-batch-cultivation claim 1 , perfusion cultivation claim 1 , and chemostat-cultivation. This application is a continuation of U.S. patent application Ser. No. 13/864,118 filed Apr. 16, 2013, which is a continuation of U.S. patent application Ser. No. 12/965,111 filed Dec. 10, 2010, issued U.S. Pat. No. 8,440,408; which is a continuation of U.S. patent application Ser. No. 11/858,844, filed Sep. 20, 2007, now abandoned; which is a division of U.S. patent application Ser. No. 10/976,399, filed Oct. 29, 2004, now abandoned; each of which applications is herein incorporated by reference in its entirety for all purposes.The present invention relates to animal protein-free cell culture media ...

Подробнее
Номер записи: 40
02-06-2022 дата публикации

HUMAN CARDIOMYOCYTE SEPARATION REAGENT, CULTURE MEDIUM, SEPARATION METHOD, AND CULTURE METHOD

Номер: US20220169989A1
Автор: HOU Yongfeng, HU Shengshou, Shi Xun, TANG Xiaoli, ZHOU Bingying
Принадлежит:

Provided are a composition containing (−)-Blebbistain and/or para-Blebbistain, a kit comprising the composition, and a cardiomyocyte culture method using the composition as a culture medium. Also provided is a use of (−)-Blebbistain and/or para-Blebbistain in preparation of a cardiomyocyte isolation reagent or cardiomyocyte culture reagent. 2. The composition of claim 1 , comprising the following components: 1-50 μM (−)-Blebbistatin claim 1 , 5-50 mM glucose claim 1 , 0.1-20 mM sodium pyruvate claim 1 , 0.1-20 mM creatine claim 1 , 5-50 mM β-aminoethanesulfonic acid claim 1 , 0.5-10 mM 4-hydroxyethyl piperazine ethanesulfonic acid (HEPES) claim 1 , 10-500 U/ml penicillin claim 1 , 10-500 μg/ml streptomycin claim 1 , 0.1-20 mM magnesium chloride claim 1 , 0.1-20 mM potassium chloride claim 1 , 10-500 mM sodium chloride claim 1 , 0.5-30 mM sodium dihydrogen phosphate claim 1 , and an appropriate amount of NaOH to make the pH of the composition be 7.0-7.8.3. A method for isolating cardiomyocytes claim 1 , comprising the steps of calcium-free perfusion claim 1 , digestion and cell collection claim 1 , wherein the composition of is used in the steps of calcium-free perfusion claim 1 , digestion and cell collection.4. A composition obtained by adding (−)-Blebbistatin and/or para-aminoblebbistatin claim 1 , antibiotics and sera to M199 medium series claim 1 , MEM medium series claim 1 , and DMEM medium series.5. The composition of claim 4 , which is obtained by adding the following components to M199 medium claim 4 , MEM-GlutaMAX medium or MEM-4-hydroxyethyl piperazine ethanesulfonic acid-GlutaMAX medium:(−)-Blebbistatin and/or para-aminoblebbistatin, wherein in the composition, the concentration of (−)-Blebbistatin is 1-50 μM, and the concentration of para- aminoblebbistatin is 1-100 μM;penicillin, and/or streptomycin, and/or Primocin, wherein the concentration of penicillin in the composition is 10-500 U/ml, the concentration of streptomycin in the composition is 10-500 ...

Подробнее
Номер записи: 41
09-06-2022 дата публикации

CELL CULTURE MEDIUM FOR EUKARYOTIC CELLS

Номер: US20220177832A1
Автор: Chen John, Golden Nathaniel, Loney Theodore, Scott Carolyn, Xue Wei
Принадлежит: Regeneron Pharmaceuticals, Inc.

Cell culture media are provided herein as are methods of using the media for cell culture and protein production from cells. 1. A method for culturing eukaryotic cells for increasing production of aflibercept , comprising the steps of:culturing eukaryotic cells expressing aflibercept in culture medium;supplementing the cell culture medium with 5-methylthioadenosine, wherein a concentration of the 5-methylthioadenosine in said cell culture medium is from about 10 nM to about 200 nM; andwherein the supplementation with 5-methylthioadenosine increases a titer of said aflibercept.2. The method of claim 1 , wherein the titer of said aflibercept is at least about 2% greater than another method with a cell culture medium that has less than 10 nM of 5-methylthioadenosine.3. The method of claim 1 , wherein the cell culture medium further comprises one or more acids selected from lactic acid claim 1 , phenyllactic acid claim 1 , indolelactic acid claim 1 , succinic acid claim 1 , alpha-hydroxyisovaleric acid claim 1 , alpha-hydroxyisocaproic acid claim 1 , 2-(4-hydroxyphenyl)lactic acid claim 1 , or 2-hydroxy-3-methylvaleric acid claim 1 , salts of these acids claim 1 , esters of these acids and combinations thereof.4. The method of claim 1 , wherein the eukaryotic cells include at least one selected from the group consisting of: baby hamster kidney cell lines claim 1 , Chinese hamster ovary cell lines claim 1 , murine myeloma cell lines claim 1 , mouse myeloma cell lines claim 1 , human embryonic kidney cell lines claim 1 , human retina-derived cell lines claim 1 , and amniocyte cell lines.5. The method of claim 1 , wherein the aflibercept is secreted in the medium.6. The method of claim 1 , wherein the cell culture medium does not have a protein derived from an animal having a pH between 6.5 and 8.0.7. The method of claim 1 , wherein the cell culture medium is a serum-free medium having a pH between 6.5 and 8.0.8. The method of claim 1 , wherein the cell culture medium is a ...

Подробнее
Номер записи: 42
09-06-2022 дата публикации

METHOD FOR LONG-TERM EX VIVO MAINTENANCE OR EXPANSION OF HUMAN ERYTHROBLAST, HUMAN MEGAKARYOCYTE-ERYTHROID PROGENITOR, OR HUMAN COMMON MYELOID PROGENITOR CELL AND APPLICATION THEREOF

Номер: US20220177842A1
Автор: Lin Yibin, LV Kangtao, TONG Chang
Принадлежит:

The invention relates to a method for long-term ex vivo maintenance or expansion of one or more of a human erythroblast, a human megakaryocyte-erythroid progenitor, or a human common myeloid progenitor, comprising the step of: culturing cells comprising one or more of those cells in a culture medium comprising one or more selected from a tankyrase inhibitor, a growth factor, a B-Raf kinase inhibitor and a GSK-3 inhibitor. 1. A method for long-term ex vivo maintenance or expansion of one or more of a human erythroblast , a human megakaryocyte-erythroid progenitor , or a human common myeloid progenitor , comprising the step of:culturing the cells comprising one or more of the human erythroblast, the human megakaryocyte-erythroid progenitor, or the human common myeloid progenitor in a culture medium, wherein the culture medium comprises one or more selected from a tankyrase inhibitor, a growth factor, a B-Raf kinase inhibitor and a GSK-3 inhibitor.2. The method of claim 1 , wherein the tankyrase inhibitor is one or more of XAV939 claim 1 , AZ-6102 claim 1 , JW-55 claim 1 , MN-64 claim 1 , TC-E 5001 claim 1 , WIKI4 claim 1 , RK-287107 claim 1 , MSC2504877 claim 1 , or G007-LK.3. The method of claim 1 , wherein the concentration of the tankyrase inhibitor in the culture medium is from 0.1 μM to 900 μM.4. The method of claim 3 , wherein the B-Raf kinase inhibitor is one or more of GDC-0879 claim 3 , PLX4032 claim 3 , GSK2118436 claim 3 , L-779450 claim 3 , DABRAFENIB claim 3 , RAF709 claim 3 , BMS-908662 claim 3 , L-779450 claim 3 , LGX818 claim 3 , PLX3603 claim 3 , RAF265 claim 3 , R05185426 claim 3 , vemurafenib claim 3 , PLX8394 claim 3 , or SB590885.5. The method of claim 3 , wherein the GSK-3 inhibitor is one or more of CHIR99021 claim 3 , CHIR98014 claim 3 , LY2090314 claim 3 , ALSTERPAULLONE claim 3 , BIO-ACETOXIME claim 3 , AZD1080 claim 3 , 2-D08 claim 3 , SB216763 claim 3 , BIO claim 3 , SB415286 claim 3 , TWS119 claim 3 , Tideglusib claim 3 , A1070722 claim 3 ...

Подробнее
Номер записи: 43
27-04-2017 дата публикации

Pluripotent cell lines and methods of use thereof

Номер: US20170114324A1
Автор: Birgitt Schüle, Blake Byers, Branden John Cord, Ha Nam Nguyen, J. William Langston, James Anthony Byrne, Renee Ann Reijo Pera, Theodore D. Palmer
Принадлежит: Leland Stanford Junior University, Parkinsons Institute

Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided.

Подробнее
Номер записи: 44
09-04-2020 дата публикации

CELL SHEET CONSTRUCT FOR NEUROVASCULAR RECONSTRUCTION AND MANUFACTURE THEREOF

Номер: US20200108176A1
Автор: CHOU Chung-Hsing, HUENG Dueng-Yuan, TSAI Tsung-Neng
Принадлежит:

The invention relates to a cell sheet construct for neurovascular reconstruction. The cell sheet construct has a vascular endothelial cell layer and a neural stem cell layer, and the two layers are physically in direct contact with each other, where the vascular endothelial cell layer forms branching vasculatures, and the neural stem cell layer differentiates into neurons. The invention also relates to a method for manufacturing the cell sheet construct, having the following steps: culturing vascular endothelial cells on a substrate to form a vascular endothelial cell layer, seeding neural stem cells on the vascular endothelial cell layer to make the neural stem cells be physically in direct contact with the vascular endothelial cell layer, and culturing the neural stem cells and the vascular endothelial cell layer to differentiate into neurons and branching vasculatures to form a cell sheet construct. 1. A method for manufacturing a cell sheet construct , consisting of:step 1. culturing vascular endothelial cells on a cell culture dish with a vascular endothelial cell medium to form a vascular endothelial cell layer;step 2. seeding neural stem cells on the vascular endothelial cell layer to ensure the neural stem cells being physically in direct contact with the vascular endothelial cell layer;step 3. co-culturing the neural stem cells and the endothelial cell layer to form a cell sheet construct of neural stem cells-vascular endothelial cells (NSC-EC);step 4. detaching the cell sheet construct of NSC-EC from the culture dish and transferring the same to a cell culture surface; andstep 5. culturing the cell sheet construct of NSC-EC with a NSC-EC co-culture medium.2. The method of claim 1 , wherein the neural stem cells are human cerebral neural stem cell line claim 1 , SCC007 claim 1 , Millipore.3. The method of claim 1 , wherein the vascular endothelial cell layer is used as a carrier.4. The method of claim 1 , wherein in step 1 claim 1 , the cell culture dish ...

Подробнее
Номер записи: 45
09-04-2020 дата публикации

Cell sheet construct for neurovascular reconstruction and manufacture thereof

Номер: US20200108177A1
Автор: Chung-Hsing CHOU, Dueng-Yuan Hueng, Tsung-Neng TSAI
Принадлежит: NATIONAL DEFENSE MEDICAL CENTER

The invention relates to a cell sheet construct for neurovascular reconstruction. The cell sheet construct has a vascular endothelial cell layer and a neural stem cell layer, and the two layers are physically in direct contact with each other, where the vascular endothelial cell layer forms branching vasculatures, and the neural stem cell layer differentiates into neurons. The invention also relates to a method for manufacturing the cell sheet construct, having the following steps: culturing vascular endothelial cells on a substrate to form a vascular endothelial cell layer, seeding neural stem cells on the vascular endothelial cell layer to make the neural stem cells be physically in direct contact with the vascular endothelial cell layer, and culturing the neural stem cells and the vascular endothelial cell layer to differentiate into neurons and branching vasculatures to form a cell sheet construct.

Подробнее
Номер записи: 46
14-05-2015 дата публикации

ENCAPSULATION AND CARDIAC DIFFERENTIATION OF hiPSCs IN 3D PEG-FIBRINOGEN HYDROGELS

Номер: US20150132847A1
Автор: Hodge Alexander J., Kerscher Petra, Lipke Elizabeth A.
Принадлежит:

The present invention relates to the production of cell cultures and tissues from undifferentiated pluripotent stem cells using three-dimensional biomimetic materials. The resultant cell cultures or tissues can be used in any of a number of protocols including testing chemicals, compounds, and drugs. Further, the methods and compositions of the present invention further provide viable cell sources and novel cell delivery platforms that allow for replacement of diseased tissue and engraftment of new cardiomyocytes from a readily available in vitro source. The present invention includes novel methods required for the successful production of cell cultures and tissues, systems and components used for the same, and methods of using the resultant cell and tissue compositions. 1. A method of producing a three-dimensional cell culture or tissue comprising:combining a population of pluripotent stem cells (PSCs) with a biomimetic material to form a biomimetic-PSC suspension;treating said biomimetic-PSC suspension to produce a three-dimensional biomimetic-PSC microenvironment; andculturing said biomimetic-PSC microenvironment to differentiate the PSCs into at least one type of somatic cell.2. The method of wherein the biomimetic material is a hydrogel.3. The method of wherein the hydrogel is a covalently-linkable hydrogel.4. The method of wherein the covalently-linkable hydrogel is a PEG-based hydrogel.5. The method of wherein the PEG-based hydrogel comprises PEG-fibrinogen.6. The method of wherein said treating said biomimetic-PSC suspension further comprises placing said biomimetic-PSC suspension into a mold.7. The method of wherein said microenvironment is selected from the group consisting of microislands claim 1 , cardiac discs claim 1 , strings claim 1 , macrotissues claim 1 , and microspheres claim 1 , and combinations thereof.8. The method of wherein said treating said biomimetic-PSC suspension to produce a three-dimensional biomimetic-PSC microenvironment comprises ...

Подробнее
Номер записи: 47
14-05-2015 дата публикации

TISSUE CULTURING METHOD, CULTURING METHOD OF FERNS AND EXPLANT OBTAINED THEREFROM

Номер: US20150132852A1
Автор: Ho Chin-Wen, KUO Chou-Chiang, Tsai Yung-Ting, Wang Kai-Ping, Wu Yu-Syuan
Принадлежит: Chunghwa Picture Tubes, LTD.

A tissue culturing method includes following steps: providing a chopped gametophyte, generating calluses by culturing the chopped gametophyte, and performing apogamic regeneration of sporophytes, by culturing the calluses in a culture fluid to develop the sporophytes from the calluses. The present invention also provides a tissue culturing method of ferns and an explant. 1. A culturing method of ferns , comprising:providing a chopped gametophyte of ferns;generating a callus, by culturing the chopped gametophyte of ferns till the chopped gametophyte generates the callus; andperforming apogamic regeneration of a sporophyte, by culturing the calluses in a culture fluid to develop the sporophyte from the callus.2. A tissue culturing method , comprising following steps:providing a chopped gametophyte;generating a callus, by culturing the chopped gametophyte till the chopped gametophyte generates the callus; andperforming apogamic regeneration of a sporophyte, by culturing the calluses in a culture fluid to develop the sporophyte from the callus.3. The tissue culturing method of claim 2 , wherein the step of generating the callus further comprises inducing the chopped gametophyte to generate the callus and proliferating a generated callus.4. The tissue culturing method of claim 2 , wherein the step of apogamic regeneration of the sporophyte further comprises sporophyte induction claim 2 , by inducing the callus to form the sporophyte claim 2 , and sporophyte proliferation claim 2 , by proliferating a formed sporophyte.5. The tissue culturing method of claim 2 , wherein the culture fluid comprises 1 wt % to 5 wt % carbon source.6. The tissue culturing method of claim 2 , wherein the culture fluid comprises ½ MS medium and 20 g/L sucrose.7. The tissue culturing method of claim 2 , wherein the step of apogamic regenerating the sporophyte comprises culturing the callus in a first culture fluid to induce the generating of the sporophyte from the callus claim 2 , and then ...

Подробнее
Номер записи: 48
23-04-2020 дата публикации

XENOBIOTIC-FREE CULTURE SYSTEM TO EXPAND HUMAN LIMBAL STEM CELLS

Номер: US20200123497A1
Автор: Deng Sophie Xiaohui, Gonzalez Sheyla
Принадлежит: The Regents of the University of California

A human limbal epithelial stem xenobiotic free cell culture system is provided. The cell culture system typically includes a cell culture media comprising isoproterenol, Human Epidermal Growth Factor (EGF), N2 supplement, hydrocortisone, and an antibiotic. This cell culture media can efficiently propagate undifferentiated LSCs in the absence xenobiotic cells. These systems provide an optimized way to culture LSCs for use in human transplantation (e.g. in patients suffering from limbal stem cell deficiency) by minimizing the risk of cross-contamination and/or reagent toxicity to transplant recipients. 1. A human limbal epithelial stem cell culture media comprising:isoproterenol;Human Epidermal Growth Factor (EGF); andan antibiotic;wherein:the media does not contain cholera toxin; and/orthe media does not contain dimethylsulfoxide (DMSO).2. The cell culture media of claim 1 , wherein the media comprises from 1% to 20% human serum (v/v).3. The cell culture media of claim 1 , wherein the media comprises at least one of:from 0.5-2 μg/mL isoproterenol;from 0.4-10 ng/mL Human Epidermal Growth Factor (EGF);from 0.4-5 μg/mL hydrocortisone; andat least one of penicillin, streptomycin, gentamicin or amphotericin B.4. The cell culture media of claim 1 , further comprising at least one of:insulin;transferrin;selenite;progesterone; andputrescine.5. The cell culture media of claim 1 , wherein the media further comprises a denuded amniotic membrane.6. The cell culture media of claim 1 , wherein the media further comprises human limbal epithelial stem cells.7. The cell culture media of claim 6 , wherein the human limbal epithelial stem cells are disposed within a limbal tissue explant.8. The cell culture media of claim 1 , wherein the media is free of xenobiotic supplements.9. The cell culture media of claim 1 , wherein human limbal epithelial stem cells growing in the media comprise greater than 3% p62α bright cells.10. The cell culture media of claim 1 , wherein the media ...

Подробнее
Номер записи: 49
21-05-2015 дата публикации

COMPOSITIONS AND METHODS FOR ENHANCING THE VIABILITY OF ANIMAL CELLS, TISSUES, AND ORGAN EXPLANTS

Номер: US20150140543A1
Автор: Drapeau Susan J., Noel Scott P., Roy Josee, Shimko Daniel Andrew
Принадлежит:

Disclosed are compositions and methods for the preservation, storage, and transport of living biological tissues, organs, and populations of isolated cells. In particular, the disclosed compositions and processes permit mammalian cells, tissues, and organs to be harvested from suitable donor animals, stored for prolonged periods, and transported to the site of recipient implantation, all without significant loss of cell viability, biological activity, and/or tissue integrity. 1. A composition comprising:a) a biological buffer, medium, tissue storage buffer or organ transport solution;b) at least a first polyethylene glycol;c) at least a first chelator selected from the group consisting of deferoxamine mesylate, 2,2′-dipyridyl, and 1,10-phenanthroline; andd) at least a first antioxidant selected from the group consisting of ascorbic acid and 2,6-di-tert-butyl-4-methylphenol;wherein each of b) c) and d) is present in said composition in an amount effective to prolong the viability of a biological sample maintained in said composition compared to maintenance of said biological sample stored in said biological buffer, medium, tissue storage buffer, or organ transport solution alone.2. The composition of claim 1 , wherein:a) said at least a first polyethylene glycol is present in said composition at a concentration of between about 0.01% (vol./vol.) and about 30% (vol./vol);b) said at least a first chelator is present in said composition at a concentration of between about 0.01 μM and about 100 μM; orc) said at least a first antioxidant is present in said composition at a concentration of between about 0.0001% (vol./vol.) and about 0.30% (vol./vol.).3. The composition of claim 1 , further comprising at least a second distinct antioxidant.4. The composition of claim 3 , wherein said at least a first antioxidant is ascorbic acid claim 3 , and said at least a second distinct antioxidant is 2 claim 3 ,6-di-tert-butyl-4-methylphenol.5. A method for storing a biological sample ...

Подробнее
Номер записи: 50
17-05-2018 дата публикации

ISOLATION AND LONG-TERM CULTURING OF ESTROGEN RECEPTOR-POSITIVE HUMAN BREAST EPITHELIAL CELLS

Номер: US20180135010A1
Автор: Christine Klitgaard Marie, Hopkinsson Branden, Jael Rubner Fridriksdottir Agla, KIM Jiyoung, Rønnov-Jessen Petersen Lone, Villadsen René, William Petersen Ole
Принадлежит:

The present invention describes methods for long-term culturing of ERcells, cell lines, and/or cell strains with exetended lifespan and/or cell strain as well as culture medium compositions. The invention further describes methods for isolating cells which may be used as starting point for long-term culturing of ERcells, cell lines, and/or cell strains with extended lifespan and/or cell strain. The invention further discloses various methods for generating ERtumorigenic cells, cell lines, and/or cell strains with extended lifespan and/or cell strain as well as various assays for their use. 1. An immortalized estrogen receptor positive cell line , wherein said cell line has a CD326/CD271phenotype.2. The cell line according to any one of the preceding claims , wherein said cell line further has a CD166/CD117phenotype.3. The cell line according to any one of the preceding claims , wherein said cell line further has a Ks20.8phenotype.4. The cell line according to any one of the preceding claims , wherein said cell line is capable of responding to estrogen.5. The cell line according to any one of the preceding claims , wherein said cell line has been immortalized by genetic modification and/or transfection.6. The cell line according to any one of the preceding claims , wherein said cell line has been immortalized by insertion of and/or transfection with of a telomerase reverse transcriptase such as a human telomerase reverse transcriptase (hTERT) gene and/or a shRNA P16 (shp16) gene.7. The cell line according to any one of the preceding claims , wherein said cell line is derived from a primary breast epithelial progenitor cell.8. The cell line according to any one of the preceding claims , wherein said cell line is derived from a primary breast epithelial luminal progenitor cell.9. The cell line according to any one of the preceding claims , wherein said cell line is derived from a cell strain as defined in any one of the - and/or cell strain with extended lifespan as ...

Подробнее
Номер записи: 51
28-05-2015 дата публикации

METHODS AND COMPOSITIONS OF PRODUCING PATIENT-SPECIFIC MULTIPOTENT NEURONAL STEM CELLS

Номер: US20150147301A1
Автор: Isaev Dmitry, Semechkin Ruslan
Принадлежит:

The present invention relates to the seminal discovery of compositions and a method of producing NSC obtained from stem cells derived from parthenogenically activated human oocytes (phNSC). The phNSC of the invention maintain proliferative and differentiation potential during cultivation and expansion. 1. An isolated neuronal stem cell , wherein the cell is differentiated from a parthenogenetically activated oocyte.2. The neuronal stem cell of claim 1 , wherein the cell is histocompatible with the oocyte donor.3. The neuronal stem cell of claim 2 , wherein the cell is histocompatible with a population group based on a matching haplotype.4. The neuronal stem cell of claim 1 , wherein the cell has a different pattern of zygosity from an ESC.5. The neuronal stem cell of claim 1 , wherein the cell contains only the maternal genome.6. The neuronal stem cell of claim 1 , wherein the cell is histocompatible with the oocyte donor claim 1 , has a different pattern of zygosity from an ESC and contains only the maternal genome.7. The neuronal stem cell of claim 1 , wherein the cell is transplantable to humans.8. The neuronal stem cell of claim 1 , wherein the cell is undifferentiated claim 1 , partially differentiated or fully differentiated.9. The neuronal stem cell of claim 1 , wherein the cell can be differentiated into a neuronal cell.10. The neuronal stem cell of claim 9 , wherein the cell can be differentiated a neuronal cell selected from the group consisting of a neuron claim 9 , a glial cell claim 9 , an oligodendrocyte and an astrocyte.11. The differentiated neuronal cell of claim 10 , wherein the cell is a neuron.12. The neuron of claim 11 , wherein the neuron is selected from the group consisting of: a cholinergic neuron claim 11 , a GABAergic neuron claim 11 , a glutamatergic neuron claim 11 , a dopaminergic neuron and a serotonergic neuron.13. The neuron of claim 12 , wherein the neuron is a dopaminergic neuron.14. The neuronal stem cell of claim 1 , wherein the ...

Подробнее
Номер записи: 52
08-09-2022 дата публикации

Anaerobic preconditioning of cells for improved in vitro protein production

Номер: US20220282286A1
Автор: Denis Tamiev, Nigel Forest Reuel
Принадлежит: Iowa State University Research Foundation ISURF

Various aspects relate to a cell-free protein expression method. The method includes exposing a microorganism to substantially anaerobic growth conditions to produce a conditioned microorganism. The method further includes lysing the conditioned microorganism to produce a lysate. The method further includes combining the lysate with a nucleic acid and producing a protein of interest a metabolic pathway, a molecule, or a mixture thereof from the lysate.

Подробнее
Номер записи: 53
09-05-2019 дата публикации

Culture method for stable proliferation of pluripotent stem cell while maintaining undifferentiated state

Номер: US20190136202A1
Автор: Ikue HARATA, Manabu Kitazawa, Nao SUGIMOTO, Satoru Okamoto, Sho SENDA, Tomomi Yoshida, Yoko KURIYAMA
Принадлежит: Ajinomoto Co Inc

Cultivating a pluripotent stem cell in a medium comprising at least one member selected from the group consisting of ethanolamine, an ethanolamine analog, and a s pharmaceutically acceptable salt thereof, and which is substantially free of β-mercaptoethanol or contains β-mercaptoethanol at a concentration of not more than 9 μM, and the like, is effective for the proliferation of a pluripotent stem cell while maintaining an undifferentiated state.

Подробнее
Номер записи: 54
10-06-2021 дата публикации

Streamlined methods for making liquid media

Номер: US20210171901A1
Автор: Deirdre EYCHNER, Gabrielle Lorenzo, Mary REYNOLDS, Matthew Kahn, Mwita PHELPS, Neva ALLES, Paul GULDE, Richard Fike, Ryan BONIFACE
Принадлежит: Life Technologies Corp

Provided herein are, inter alia, methods for preparing a liquid cell culture media that has lesser lot-to-lot analytical variation, increased performance, and has lesser metal ion concentrations compared to a liquid media prepared by traditional methods. Such liquid media may be used for culturing cells, including but not limited to, recombinant cells.

Подробнее
Номер записи: 55
25-05-2017 дата публикации

Method for stem cell differentiation in vivo by delivery of morphogenes with mesoporous silica and corresponding pharmaceutical active ingredients

Номер: US20170145382A1
Автор: Alfonso E. Garcia-Bennett, Elena Nickolaevna Kozlova
Принадлежит: Nanologica AB

A pharmaceutical active ingredient for cell differentiation to alleviate cell and cell-related deficiencies in mammals comprising porous silica containing a releasable agent capable of contributing to a cell environment conducive for stem cell differentiation in co-implanted stem cells and/or in endogenous stem cells.

Подробнее
Номер записи: 56
16-05-2019 дата публикации

CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION

Номер: US20190144817A1
Автор: MEIER Steven J., VARMA Sharat, VIJAYASANKARAN Natarajan, Yang Yi
Принадлежит: Genentech, Inc.

Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided. 164-. (canceled)65. A method of producing a recombinant polypeptide composition with reduced color intensity , comprising the steps of:culturing a cell comprising a nucleic acid encoding the recombinant polypeptide in a cell culture medium, wherein the cell culture medium comprises aminoguanidine;producing the recombinant polypeptide;wherein the cell culture medium comprising the aminoguanidine reduces the color intensity of a composition comprising the recombinant polypeptide produced by the cell as compared to a composition comprising the recombinant polypeptide produced by the cell cultured in a cell culture medium that does not comprise the aminoguanidine.66. The method of claim 65 , wherein the cell culture medium comprising the aminoguanidine reduces the color intensity of a composition comprising the recombinant polypeptide produced by the cells by at least about 0.1% as compared to a composition comprising the recombinant polypeptide produced by the cell cultured in a cell culture medium that does not comprise the aminoguanidine.67. The method of claim 65 , wherein the cell culture medium comprising the aminoguanidine reduces the color intensity of a composition comprising the recombinant polypeptide produced by the cells by about 5% to about 50% as compared to a composition comprising the recombinant polypeptide produced by the cell cultured in a cell culture medium that does not comprise the aminoguanidine.68. The method of claim 65 , wherein the cell culture medium comprises the aminoguanidine at a concentration from at least about 0.0003 mM.6975-. (canceled)76. The method of claim 65 , wherein the cell culture medium comprises aminoguanidine at a concentration from about 0.0003 mM ...

Подробнее
Номер записи: 57
11-06-2015 дата публикации

Compounds for improved stem cell differentiation into hepatocytes

Номер: US20150158840A1
Автор: Brian Leonard, Eric Chiao, Matthew Michael Hamilton, Miriam Triyatni, Sei KAMEOKA
Принадлежит: F Hoffmann La Roche AG

The invention relates to the compounds of formula I and pharmaceutically acceptable salts and esters thereof, wherein R 1 -R 11 are as defined in the description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are useful in differentiating stem cells into more mature or adult-like hepatocytes for use as drug screening platforms and in disease modeling applications.

Подробнее
Номер записи: 58
11-06-2015 дата публикации

SMAC Mimetic for Treating Myelodysplastic Syndromes

Номер: US20150158908A1
Автор: CONDON Stephen M., DENG Yijun, LaPorte Matthew G., Rippin Susan R.
Принадлежит:

A SMAC mimetic and pharmaceutical compositions thereof and methods of use. 3. The pharmaceutical composition of for the treatment of a proliferative disorder.4. The pharmaceutical composition of for the treatment of a cancer.5. The pharmaceutical composition of which is a sterile liquid for injection.6. The pharmaceutical composition of which is in a unit dose form.7. A method of treating a proliferative disorder in a mammal in need thereof that comprises internally administering to the animal an effective amount of Compound 15.8. The method of wherein the proliferative disorder is a cancer selected from the group consisting of: lung adenocarcinoma claim 7 , pancreatic cancer claim 7 , colon cancer claim 7 , ovarian cancer claim 7 , breast cancer claim 7 , mesothelioma claim 7 , peripheral neuroma claim 7 , bladder cancer claim 7 , glioblastoma claim 7 , melanoma claim 7 , adrenocortical carcinoma claim 7 , AIDS-related lymphoma claim 7 , anal cancer claim 7 , bladder cancer claim 7 , meningioma claim 7 , glioma claim 7 , astrocytoma claim 7 , breast cancer claim 7 , cervical cancer claim 7 , chronic myeloproliferative disorders (e.g. claim 7 , chronic lymphocytic leukemia claim 7 , chronic myelogenous leukemia) claim 7 , colon cancer claim 7 , endocrine cancers claim 7 , endometrial cancer claim 7 , ependymoma claim 7 , esophageal cancer claim 7 , Ewing's sarcoma claim 7 , extracranial germ cell tumors claim 7 , extragonadal germ cell tumors claim 7 , extrahepatic bile duct cancer claim 7 , gallbladder cancer claim 7 , gastric cancer claim 7 , gastrointestinal carcinoid tumors claim 7 , gestational trophoblastic tumors claim 7 , hairy cell leukemia claim 7 , Hodgkin lymphoma claim 7 , non-Hodgkin lymphoma claim 7 , hypopharyngeal cancer claim 7 , intraocular melanoma claim 7 , islet cell carcinoma claim 7 , Kaposi sarcoma claim 7 , laryngeal cancer claim 7 , leukemia claim 7 , acute lymphoblastic leukemia claim 7 , acute myeloid leukemia claim 7 , lip cancer claim ...

Подробнее
Номер записи: 59
11-06-2015 дата публикации

METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELLS

Номер: US20150159134A1
Автор: CHOUDHARY PARUL, FOX HEATHER DAWN ELLEN, SURMACZ-CORDLE BEATA, WHITING PAUL JOHN
Принадлежит: PFIZER LIMITED

The invention relates to a method for producing retinal pigment epithelial cells. 1. A method for producing retinal pigment epithelial (RPE) cells comprising the steps of:(a) culturing pluripotent cells in the presence of a first SMAD inhibitor and a second SMAD inhibitor;(b) culturing the cells of step (a) in the presence of a BMP pathway activator and in the absence of the first and second SMAD inhibitors; and,(c) replating the cells of step (b).2. The method according to wherein claim 1 , in step (a) claim 1 , the cells are cultured as a monolayer.3. The method according to or wherein claim 1 , in step (b) claim 1 , the cells are cultured as a monolayer.4. The method according to wherein claim 1 , in step (a) claim 1 , the cells are cultured in a suspension culture.5. The method according to any one of claim 1 , or wherein claim 1 , in step (b) claim 1 , the cells are cultured in a suspension culture.6. The method according to any one of to claim 1 , wherein the pluripotent cells are selected from embryonic stem cells or induced pluripotent stem cells.7. The method according to any one of to claim 1 , wherein the pluripotent cells are human cells.8. The method according to any one of to claim 1 , wherein the pluripotent cells are human embryonic stem cells.9. The method according to any one of to claim 1 , wherein the pluripotent cells are human induced pluripotent stem cells.10. The method according to any one of to claim 1 , wherein the pluripotent cells are obtained by means which do not require the destruction of a human embryo.11. The method according to any one of to wherein the first SMAD inhibitor is an inhibitor of BMP type 1 receptor ALK2.12. The method according to any one of to wherein the first SMAD inhibitor is an inhibitor of BMP type 1 receptors ALK2 and ALK3.13. The method according to any one of to wherein the first SMAD inhibitor prevents Smad1 claim 1 , Smad5 and/or Smad8 phosphorylation.14. The method according to any one of to wherein the ...

Подробнее
Номер записи: 60
07-06-2018 дата публикации

Compositions for treatment of osteochondral disorders

Номер: US20180153940A1
Автор: Frank Luyten, Johanna BOLANDER, Veerle BLOEMEN
Принадлежит: Katholieke Universiteit Leuven

The application provides biocompatible carriers comprising bone forming and/or cartilage forming cells and methods for making them. The application further provides pharmaceutical compositions comprising said ATMPs and method of treatments using said ATMPs. The application further relates to said ATMPS for use in the treatment of bone disorders, cartilage disorders and joint disorders. The current invention further relates to method of treatments of bone disorders, cartilage disorders and joint disorders.

Подробнее
Номер записи: 61
18-06-2015 дата публикации

SMOOTHENED MODULATORS AND METHODS OF USE THEREOF

Номер: US20150166509A1
Автор: Barak Lawrence S., Chen Wei, JR. Robert A., Lyerly H. Kim, Mook, Ribeiro Anthony Angelo, WANG Jiangbo
Принадлежит:

Compounds of general Formulas (I), (IA), (IB) are described, along with compositions containing the same and methods of use thereof, inhibiting the hedgehog pathway in a cell or inhibiting unwanted proliferation of a cell. 2. The compound of claim 1 , wherein:X is C, Y is C, and Z is N;X is C, Y is N, and Z is C;X is N, Y is C, and Z is C;3. The compound of claim 1 , wherein:X is N, Y is N, and Z is C;X is N, Y is C, and Z is N; orX is C, Y is N, and Z is N.4. The compound of claim 1 , wherein said compound has the structure of Formula IB and R is heterocyclo.7. The compound of claim 1 , wherein R is selected from the group consisting of H claim 1 , alkyl claim 1 , cycloalkyl claim 1 , cycloalkylalkyl claim 1 , heterocyclo claim 1 , heterocycloalkyl claim 1 , heterocycloalkenylaryl claim 1 , arylalkyl claim 1 , arylalkenyl claim 1 , arylalkynyl claim 1 , heteroaryl claim 1 , heteroarylalkyl claim 1 , heteroarylalkenyl claim 1 , alkoxy claim 1 , halo claim 1 , cyano claim 1 , hydroxyl claim 1 , acyl claim 1 , aryloxy claim 1 , alkylthio claim 1 , amino claim 1 , alkylamino claim 1 , arylalkylamino claim 1 , disubstituted amino claim 1 , acylamino claim 1 , acyloxy claim 1 , ester claim 1 , amide claim 1 , sulfoxyl claim 1 , sulfonyl claim 1 , sulfonamide claim 1 , urea claim 1 , alkoxylacylamino claim 1 , and aminoacyloxy.8. The compound of claim 1 , wherein Ris selected from the group consisting of H claim 1 , alkyl claim 1 , cycloalkyl claim 1 , cycloalkylalkyl claim 1 , cycloalkylalkenyl claim 1 , heterocyclo claim 1 , heterocycloalkyl claim 1 , heterocycloalkenyl claim 1 , aryl claim 1 , arylalkyl claim 1 , arylalkenyl claim 1 , heteroaryl claim 1 , heteroarylalkyl claim 1 , heteroarylalkenyl claim 1 , alkoxy claim 1 , halo claim 1 , cyano claim 1 , hydroxyl claim 1 , acyl claim 1 , aryloxy claim 1 , alkylthio claim 1 , amino claim 1 , alkylamino claim 1 , arylalkylamino claim 1 , disubstituted amino claim 1 , acylamino claim 1 , acyloxy claim 1 , ester claim 1 , ...

Подробнее
Номер записи: 62
18-06-2015 дата публикации

NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL

Номер: US20150166526A1
Автор: Merikapudi Gayatri S., MUTHUPPALANIAPPAN Meyyappan, Vakkalanka Swaroop K., Viswanadha Srikant
Принадлежит:

Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer. 7. A compound of claim 1 , wherein Land Ltogether represent —NH—C(═O)— claim 1 , —NH—S(═O)— claim 1 , —C(═O)NH— or NH—CH—.8. A compound of claim 7 , wherein Land Ltogether represent —NH—C(═O)— claim 7 , —C(═O)NH— or S(═O)NH— claim 7 , —NH—CH—.9. A compound of claim 1 , wherein A is absent or is selected from —(CR′R″)— or —NR.10. A compound of claim 9 , wherein A is —CH— or —CHMe— claim 9 , (CR′R″)— claim 9 , where R′ and R″ are joined to form a substituted or unsubstituted saturated or unsaturated 3-6 membered ring claim 9 , which may optionally include one or more heteroatoms which are the same or different and are selected from O claim 9 , NRand S.16. A compound of claim 15 , wherein{'sub': 1', '2, 'Land Ltogether represent —NH—C(O)—; and'}Cy is selected from monocyclic substituted or unsubstituted aryl, and monocyclic substituted or unsubstituted heteroaryl.17. A compound of claim 15 , wherein both Rand Rrepresent cyclopropyl.18. A compound of claim 15 , wherein one of Rand Ris CFand the other is independently cyclopropyl claim 15 , CHF or CHF.19. A compound of claim 15 , wherein T claim 15 , U claim 15 , V claim 15 , and W are independently CH claim 15 , CF or N.20. A compound of claim 19 , wherein T is CF or N and each of U claim 19 , V and W is CH.21. A compound of claim 19 , wherein each of T and V is independently CF or N and each of U and W is CH.22. A compound of claim 15 , wherein Land Ltogether represent —NH—C(═O)— claim 15 , —NH—S(═O)— claim 15 , —C(═O)NH— or NH—CH—.23. A compound of claim 15 , wherein A is absent claim 15 , —NH— claim 15 , or —CH—.24. A compound of ...

Подробнее
Номер записи: 63
18-06-2015 дата публикации

IMMUNOLOGICAL REAGENTS AND USES THEREFOR

Номер: US20150166542A1
Автор: Corbett Alexandra, Fairlie David Paul, Kjer-Nielsen Lars, Liu Ligong, McCluskey James, Onisha Patel, Rossjohn Jamie
Принадлежит: THE UNIVERSITY OF MELBOURNE

The present invention provides a ligand which binds to MR1 wherein said binding results in binding of the MR1 to MAIT cells. 1. A ligand which binds to MR1 wherein said binding results in binding of the MR1 to MAIT cells.2. The ligand according to claim 1 , wherein said ligand binds in a binding cleft formed by the α1 and α2 domains of MR1.3. The ligand according to claim 1 , wherein when said ligand is bound to a MAIT cell the MAIT cell is stimulated or inhibited via its TCR.4. The ligand according to claim 1 , wherein said binding of the ligand to MR1 causes refolding of the MR1 into a form capable of binding to MAIT cells.6. The ligand according to claim 5 , wherein said ligand is 6-formyl pterin claim 5 , acetyl 6-formyl pterin or a functional analogue thereof.7. The ligand according to claim 5 , wherein said ligand is rRL-6AM claim 5 , rRL-6HM claim 5 , RL-6M claim 5 , RP-SPA claim 5 , 6-methyl-7-hydroxy-8-ribityl lumazine claim 5 , 6- claim 5 ,7-dimethyl-8-Ribityl Lumazine or a functional analogue thereof including oxidised and reduced forms thereof.8. The ligand according to claim 1 , wherein the MR1 polypeptide comprises all or part of SEQ ID NO: 1 claim 1 , SEQ ID NO: 4 claim 1 , or a functional derivative thereof having one or more amino acid substitutions claim 1 , additions and/or deletions to SEQ ID NO: 1 or SEQ ID NO: 4.9. The ligand according to claim 8 , wherein said MR1 comprises at least one mutation selected from the list consisting of K43A claim 8 , K43M claim 8 , K43I claim 8 , K43L claim 8 , K43F claim 8 , K43Q claim 8 , Y7A claim 8 , Y7W claim 8 , R9K claim 8 , R9A claim 8 , S24F claim 8 , Y62A claim 8 , L66A claim 8 , L66F claim 8 , W69A claim 8 , R94K claim 8 , R94A claim 8 , I96A claim 8 , I96F and W156A.10. The ligand according to claim 8 , wherein said MR1 comprises one or more mutations in surface exposed groups selected from the list consisting of D57 claim 8 , R61 claim 8 , L65 claim 8 , M72 claim 8 , V75 claim 8 , R79 claim 8 , T138 ...

Подробнее
Номер записи: 64
14-05-2020 дата публикации

SERUM-FREE CELL CULTURE MEDIUM

Номер: US20200149081A1
Автор: JOHNSON Amy S., LAWRENCE Shawn M., OSHODI Shadia Abike
Принадлежит:

The specification describes an improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Ornithine, or a combination of ornithine and putrescine can be added to serum-free media or chemically defined media to improve viable cell density, to reduce cell doubling time, and to increase the production of a protein of interest. 1. A method for cultivating a cell expressing aflibercept , comprising:(a) providing a cell culture medium comprising 0.6±0.09 mM ornithine and 0.714±0.11 mM putrescine, wherein said medium is serum-free and hydrolysate-free; and(b) propagating or maintaining the cell in said cell culture medium to form a cell culture.2. The method of claim 1 , wherein the cell culture medium is chemically defined.3. The method of claim 1 , wherein the cell culture medium comprises ≥40±6 mM of a mixture of amino acids or salts thereof.4. The method of claim 3 , wherein the mixture of amino acids or salts thereof comprises alanine claim 3 , arginine claim 3 , asparagine claim 3 , aspartic acid claim 3 , cysteine claim 3 , glutamic acid claim 3 , glycine claim 3 , histidine claim 3 , isoleucine claim 3 , leucine claim 3 , lysine claim 3 , methionine claim 3 , phenylalanine claim 3 , proline claim 3 , serine claim 3 , threonine claim 3 , tryptophan claim 3 , tyrosine claim 3 , and valine.5. The method of claim 1 , wherein the cell culture medium comprises one or more fatty acids.6. The method of claim 5 , wherein the one or more fatty acids are selected from the group consisting of linoleic acid claim 5 , thioctic acid claim 5 , oleic acid claim 5 , palmitic acid claim 5 , stearic acid claim 5 , arachidic acid claim 5 , arachidonic acid claim 5 , lauric acid claim 5 , behenic acid claim 5 , decanoic acid claim 5 , dodecanoic acid claim 5 , hexanoic acid claim 5 , lignoceric acid claim 5 , myristic acid and octanoic acid.7. The method of claim 1 , wherein the cell culture medium comprises a mixture of nucleosides.8. ...

Подробнее
Номер записи: 65
14-06-2018 дата публикации

DEEP EUTECTIC SOLVENTS AND/OR IONIC LIQUIDS IN CELL CULTURE MEDIA

Номер: US20180163171A1
Автор: KNACK Claudia, RAYNER Michael Howard, SIECK Jochen Bastian, von Hagen Joerg
Принадлежит: Merck Patent GmBH

The present invention relates to cell culture media compositions comprising deep eutectic solvents and/or ionic liquids. 1. A cell culture medium composition comprising a dry cell culture medium component and a liquid cell culture medium component which comprises a deep eutectic solvent and/or an ionic liquid.2. A cell culture medium composition according to claim 1 , characterized in that the cell culture medium composition is a base medium or a feed medium.3. A cell culture medium composition according to claim characterized in that the liquid cell culture medium component of the cell culture medium composition is liquid at or below 35° C.4. A cell culture medium composition according to claim 1 , characterized in that the liquid cell culture medium component comprises a deep eutectic solvent.5. A cell culture medium composition according claim 1 , characterized in that the liquid cell culture medium component comprises a quaternary ammonium salt.6. A cell culture medium composition according claim 1 , characterized in that the liquid cell culture medium component comprises choline and/or betaine.7. A cell culture medium composition according claim 1 , characterized in that the liquid cell culture medium component comprises amino acids claim 1 , preferably cysteine and/or tyrosine.8. A cell culture medium composition according to claim 1 , characterized in the liquid cell culture medium component comprises other ingredients which are not part of the ionic liquid or deep eutectic solvent and which are dissolved in the ionic liquid and/or deep eutectic solvent.9. A process for cell culture comprising the following steps:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a) Providing a bioreactor and a cell culture media composition according to'}b) Dissolving the cell culture media composition in a solvent to generate a liquid cell culture mediumc) Adding to the bioreactor the liquid cell culture medium of step b) either as a base medium to which the cells are added ...

Подробнее
Номер записи: 66
25-06-2015 дата публикации

Media for Cell Culture

Номер: US20150175956A1
Автор: Elhofy Adam, Weber Allan
Принадлежит:

The present disclosure relates, in general, to a media, e.g., a serum replacement, media supplement, complete media or cryopreservation media, comprising a base physiological buffer and liposomes comprising cholesterol, phosphatidylcholine and fatty acids. It is contemplated that media provides advantages to improve cell growth in culture compared to cells cultured not using the serum replacement described herein. 1. A media for use with cells in suspension or in adherent culture , the media comprising a base physiological buffer liquid mix and(a) liposomes comprising cholesterol, phosphatidylcholine and fatty acids, wherein the liposome is in an amount such that the final concentration of cholesterol in a cell suspension or adherent culture is from 1 to 20 mg/L, and wherein the final concentration of phosphatidylcholine in a cell suspension or adherent culture is from 100 to 1000 mg/L; or(b) pectin; or(a) and (b).2. The media of claim 1 , wherein the liposome comprises one or more fatty acids selected from the group consisting of linolenic acid claim 1 , linoleic acid claim 1 , myristic acid and oleic acid.3. The media of claim 1 , wherein the liposome further comprises ethanolamine and polysorbate.4. The media of claim 1 , wherein the final concentration of pectin in a cell suspension or adherent culture is from 25 to 500 mg/L.5. The media of claim 1 , wherein the base physiological buffer liquid mix comprises one or more organic salt claim 1 , inorganic salt claim 1 , buffer claim 1 , iron source or iron transporter claim 1 , glycerol claim 1 , amino acid claim 1 , vitamin claim 1 , sugar claim 1 , antioxidant and trace element.612-. (canceled)13. The media of claim 1 , wherein the media is a serum replacement claim 1 , complete media claim 1 , media supplement or cryopreservation media.14. A serum replacement claim 1 , complete media or media supplement comprising liposomes and a base physiological buffer liquid mix claim 1 , wherein the liposomes comprise ...

Подробнее
Номер записи: 67
25-06-2015 дата публикации

Nogo Receptor Binding Protein

Номер: US20150177240A1
Автор: LEE DANIEL H.S., McCoy John, MI SHA, Pepinsky R. Blake
Принадлежит:

The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof. 157-. (canceled)58. A method for identifying an oligodendrocyte in a tissue sample , the method comprising contacting the tissue sample with an anti-Sp35 antibody or an Sp35-binding fragment thereof and an anti-O4 oligodendrocyte marker antibody or an O4-binding fragment thereof , wherein a cell that specifically binds both the anti-Sp35 antibody or Sp35-binding fragment thereof and the anti-O4 antibody or O4-binding fragment thereof is identified as an oligodendrocyte.59. The method of claim 58 , wherein the tissue sample is a spinal cord sample.60. The method of claim 58 , wherein the tissue sample is a primary granular neuron culture.61. The method of claim 58 , wherein the tissue sample is a frontal cortex sample.62. The method of claim 58 , wherein the tissue sample is a posterior cortex sample.63. The method of claim 58 , wherein the tissue sample is an entorhinal cortex sample.64. The method of claim 58 , wherein the tissue sample is a hippocampus sample.65. The method of claim 58 , wherein the tissue sample is an olfactory bulb sample.66. The method of claim 58 , wherein the tissue sample is selected from the group consisting of a striatum sample claim 58 , a thalamus sample claim 58 , a cerebellum sample claim 58 , a midbrain sample claim 58 , a pons sample claim 58 , and a medulla sample.67. A method for identifying a neuron in a tissue sample claim 58 , the method comprising contacting the tissue sample with an anti-Sp35 antibody or an Sp35-binding fragment thereof and an anti-βIII tubulin neuronal marker antibody or an βIII tubulin-binding fragment thereof claim 58 , wherein a cell that specifically binds ...

Подробнее
Номер записи: 68
01-07-2021 дата публикации

BASAL MEDIA FOR GROWING NK-92 CELLS

Номер: US20210198628A1
Автор: ANDERSON Richard John, GOULDING John Charles
Принадлежит:

Provided herein are methods and customized media compositions for culturing NK-92® cells. 1. A method of culturing NK-92® cells comprising culturing NK-92® cells in a customized NK-92® culture medium comprising a basal medium and one or more supplements ,wherein the one or more supplements comprise ethanolamine, an ethanolamine derivative, insulin, transferrin, sodium selenite, HA, or a combination thereof; andwherein the basal medium comprises inorganic salts, vitamins and amino acids.2. The method of claim 1 , wherein the ethanolamine derivative is an ethanolamide.3. The method of claim 2 , wherein the ethanolamide is vaccenic acid ethanolamide claim 2 , or oleic acid ethanolamide claim 2 , palmitic acid ethanolamide claim 2 , or stearic acid ethanolamide claim 2 ,4. The method of claim 1 , wherein the ethanolamine derivative is phosphatidylethanolamine.5. The method of any of - claim 1 , wherein the one or more supplements comprise 1-7% human AB serum.6. The method of any of - claim 1 , wherein the one or more supplements further comprise insulin claim 1 , transferrin claim 1 , selenium claim 1 , or a combination thereof.7. The method of any of - claim 1 , wherein the one or more supplements further comprise 300-600 IU/mL interleukin-2.8. The method of any of - claim 1 , wherein the one or more supplements further comprise 0.01% to 0.1% of poloxamer 188.9. The method of any of - claim 1 , wherein the NK-92® cells cultured in the customized NK-92® culture medium have substantially the same or higher cytotoxicity claim 1 , growth rate claim 1 , and viability compared to NK-92® cells grown in a reference growth medium.10. The method of any of - claim 1 , wherein the NK-92® cells cultured in the customized NK-92® culture medium have 85-100% viability.11. The method of any of - claim 1 , wherein the NK-92® cells cultured in the customized NK-92® culture medium show a direct cytotoxicity of and/or an ADCC of 60-100% at an effector to target ratio of 10:1.12. The method ...

Подробнее
Номер записи: 69
23-06-2016 дата публикации

SERUM-FREE IN VITRO DIRECTED DIFFERENTIATION PROTOCOL FOR GENERATING STEM CELL-DERIVED BETA CELLS AND USES THEREOF

Номер: US20160177267A1
Автор: Gürtler Mads, Melton Douglas A.
Принадлежит:

Disclosed herein are methods for generating SC-β cells using chemically defined, completely serum free media, and isolated populations of SC-β cells for use in various applications, such as cell therapy. 1. A method of generating at least one SC-β cell , the method comprising: differentiating at least one PDX1+ , NKX6.1+ , insulin+ endocrine cell in a population into at least one SC-β cell by treatment with a first chemically defined , serum free medium that is supplemented with at least i) a transforming growth factor β (TGF-β) signaling pathway inhibitor , ii) a thyroid hormone signaling pathway activator , iii) insulin , iv) heparin , and v) a water soluble antioxidant , thereby generating at least one SC-β cell that exhibits a GSIS response in vitro and/or in vivo.2. The method of claim 1 , further comprising washing the cells in the population with CMRLM before treatment with the first medium.3. The method of claim 1 , wherein the first medium comprises CMRL 1066 with 2.2 g/L NaHCO claim 1 , but without HEPES claim 1 , 1% Pen/Strep claim 1 , and 2 mM Glutamax.4. The method of claim 1 , wherein the first medium is supplemented with FAF-BSA claim 1 , human APO-transferrin claim 1 , trace minerals A+B claim 1 , ZnSO4 claim 1 , ethanolamine claim 1 , pyruvate claim 1 , and defined lipids.5. The method of claim 1 , wherein the first medium is replenished every second day during a 14 day differentiation period.6. The method of claim 1 , wherein the at least one PDX1+ claim 1 , NKX6.1+ claim 1 , insulin-positive endocrine cell is obtained by differentiating at least one PDX1+ claim 1 , NKX6.1+ pancreatic progenitor cell in the population into at least one PDX1+ claim 1 , NKX6.1+ claim 1 , insulin-positive endocrine cell by treatment with a second chemically defined claim 1 , serum free medium that is supplemented with at least i) heparin claim 1 , ii) an EGF family growth factor claim 1 , iii) a retinoic signaling pathway activator claim 1 , iv) a sonic hedgehog ...

Подробнее
Номер записи: 70
09-07-2015 дата публикации

AGGLOMERATED MICROBIOLOGICAL MEDIA

Номер: US20150191692A1
Автор: Liu Jie J., Xia Wensheng
Принадлежит:

A method of making a flowable, dried agglomerated nutrient medium is provided. The method comprises introducing a nutrient component comprising a powdered nutrient, and an agglomeration liquid, into an agglomerator comprising a flow-through-type agglomeration chamber, wet-massing the nutrient component with the agglomeration liquid in the agglomeration chamber for a predetermined period of time to form agglomerated nutrient medium particles, and exposing the agglomerated nutrient medium particles to drying conditions for a period of time to form the dried, agglomerated nutrient medium. The nutrient component facilitates the growth of a microorganism. Compositions, articles, and kits comprising the flowable, dried agglomerated nutrient medium are also provided. 1. A method of making a flowable , dried agglomerated nutrient medium , the method comprising: wherein the nutrient component facilitates the growth of a microorganism;', 'wherein the agglomeration liquid is introduced as an atomized spray;, 'introducing a nutrient component comprising a powdered nutrient, and an agglomeration liquid, into an agglomerator comprising a flow-through-type agglomeration chamber;'}wet-massing the nutrient component with the agglomeration liquid in the agglomeration chamber for a predetermined period of time to form agglomerated nutrient medium particles; andexposing the agglomerated nutrient medium particles to drying conditions for a period of time to form the dried, agglomerated nutrient medium.2. The method of claim 1 , wherein the agglomeration liquid consists of water.3. The method of claim 1 , wherein the agglomeration liquid comprises a solvent having a dissolved nutrient that facilitates the growth of a microorganism.4. The method of claim 1 , wherein introducing a nutrient component comprises introducing a substantially uniform mixture of two or more powdered nutrients.5. The method of :wherein introducing a nutrient component into the agglomeration chamber comprises ...

Подробнее
Номер записи: 71
16-07-2015 дата публикации

COMPOUNDS FOR IMPROVED STEM CELL DIFFERENTIATION INTO HEPATOCYTES

Номер: US20150197726A1
Автор: Chiao Eric, Hamilton Matthew Michael, Kameoka Sei, LEONARD Brian, Triyatni Miriam
Принадлежит:

The invention relates to the compounds of formula I and pharmaceutically acceptable salts and esters thereof, wherein R-Rare as defined in the description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are useful in differentiating stem cells into more mature or adult-like hepatocytes for use as drug screening platforms and in disease modeling applications. 2. A compound of wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Rare all hydrogen.3. A compound of wherein at least one of R claim 1 , R claim 1 , R claim 1 , R claim 1 , or Ris halogen.4. A compound of wherein at least one of R claim 1 , R claim 1 , R claim 1 , R claim 1 , or Ris fluoro.5. A compound of wherein R claim 1 , R claim 1 , and Rare all hydrogen and one of Ror Ris fluoro and the other is hydrogen.6. A compound of wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Rare all hydrogen.7. A compound of wherein at least one of R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Ris halogen.8. A compound of wherein at least one of R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Ris chloro.9. A compound of wherein R claim 1 , R claim 1 , and Rare all hydrogen and one of Ror Ris chloro and the other is hydrogen.10. A compound of wherein Ris hydrogen.11. A compound of wherein one of R claim 1 , R claim 1 , R claim 1 , R claim 1 , or Ris fluoro and the others hydrogen; and R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Rare hydrogen.12. A compound of wherein Ris hydroxy.13. A compound of wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , or Ris fluoro and the others hydrogen; R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Rare hydrogen claim 1 , and Ris hydroxy.23. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.24. A method for differentiating stem ...

Подробнее
Номер записи: 72
05-07-2018 дата публикации

DIFFERENTIATING INDUCED PLURIPOTENT STEM CELLS INTO GLUCOSE-RESPONSIVE, INSULIN-SECRETING PROGENY

Номер: US20180187161A1
Автор: IKEDA Yasuhiro, Kudva Yogish C., Terzic Andre, Thatava Tayaramma
Принадлежит: Mayo Foundation for Medical Education and Research

This document provides methods and materials related to differentiating iPS cells into glucose-responsive, insulin-secreting progeny. For example, methods and material for using indolactam V (ILV) and glucagon like peptide-1 (GLP-1) to produce glucose-responsive, insulin-secreting progeny from iPS cells are provided. 1. (canceled)2. A method for obtaining a population of glucose-responsive , insulin-secreting cells from a human , wherein said method comprises:(a) obtaining somatic cells from a human,(b) exposing said somatic cells to one or more polypeptides or nucleic acids encoding said one or more polypeptides to form induced pluripotent stem cells, wherein said one or more polypeptides are selected from the group consisting of a Oct3/4 polypeptide, a Sox family polypeptide, a Klf family polypeptide, a Myc family polypeptide, a Nanog polypeptide, and a Lin28 polypeptide, and(c) culturing said induced pluripotent stem cells with medium comprising indolactam V and glucagon like peptide-1 to obtain said population of glucose-responsive, insulin-secreting cells.3. The method of claim 2 , wherein said medium lacks serum.4. The method of claim 2 , wherein said culturing is performed in the absence of feeder cells.5. The method of claim 2 , wherein said culturing is performed in the absence of non-human feeder cells.6. The method of claim 2 , wherein said somatic cells are selected from the group consisting of skin claim 2 , lung claim 2 , heart claim 2 , stomach claim 2 , brain claim 2 , liver claim 2 , blood claim 2 , kidney claim 2 , and muscle cells.7. The method of claim 2 , wherein said induced pluripotent stem cells comprise exogenous nucleic acid encoding a human Oct4 polypeptide claim 2 , a human Sox2 polypeptide claim 2 , a human Klf4 polypeptide claim 2 , and a human c-Myc polypeptide.8. The method of claim 2 , wherein said medium comprises between about 200 nM and about 400 nM of indolactam V.9. The method of claim 2 , wherein said medium comprises between ...

Подробнее
Номер записи: 73
06-07-2017 дата публикации

COMPOUNDED MEDIA POWDER FORMULATION AND METHOD OF PREPARATION OF LIQUID MEDIUM FOR CELL CULTURE

Номер: US20170191025A1
Автор: MÖHRLE Volker, Shimoni Yuval
Принадлежит: Bayer HealthCare LLC

The present invention provides a compounded cell culture medium powder formulation comprising: a basal medium powder and a cell culture media supplement, wherein the cell culture media supplement comprises and one or more salts; one or more growth factors; one or more inorganic ions; an amino acid supplement comprising one or more of asparagine, glutamine, histidine, and serine; one or more buffers; and one or more anti-foaming agents. The invention further provides methods of making a compounded cell culture medium powder formulation methods of making a cell culture medium for growing mammalian cells and methods of producing a protein of interest by culturing cells in the cell culture medium and isolating the protein of interest. 1. A compounded cell culture medium powder formulation comprising a basal medium powder and a cell culture media supplement , wherein the cell culture media supplement comprisesi) one or more salts;ii) one or more growth factors;iii) one or more inorganic ions;iv) an amino acid supplement comprising one or more of asparagine, glutamine, histidine, and serine;v) one or more buffers; andvi) one or more anti-foaming agents.2. The compounded cell culture medium powder formulation of claim 1 , wherein the basal medium powder comprises Dulbecco's Modified Eagle's Medium claim 1 , Ham's Medium F12 claim 1 , Eagle's Minimal Essential Medium claim 1 , RPMI 1640 Medium claim 1 , and Dulbecco's Modified Eagle's Medium/Ham's F12 Medium (DMEM/F-12; 1:1 ratio).3. The compounded cell culture medium powder formulation of claim 1 , wherein the basal medium powder comprises one or more of the following components or a combination thereof: biotin claim 1 , calcium chloride claim 1 , choline chloride claim 1 , cyanocobalamin (B12) claim 1 , D+ mannose claim 1 , D-calcium pantothenate claim 1 , dextrose (anhydrous) claim 1 , DL-alpha-lipoic acid claim 1 , ferric nitrate 9HO claim 1 , ferrous sulfate 7HO claim 1 , folic acid claim 1 , glycine claim 1 , ...

Подробнее
Номер записи: 74
23-07-2015 дата публикации

Inhibitors of Voltage Gated Ion Channels

Номер: US20150203812A1
Автор: Tombola Francesco
Принадлежит:

Certain embodiments of the present invention provide compounds that comprise at least one guanidine moiety and have a binding affinity for the voltage sensing domain (VSD) of a voltage-gated ion channel, such as the Hv1 voltage-gated proton channel. In some embodiments, the compounds of the present invention that have as VSD binding affinity are further characterized by having a property of inhibiting ion transport by the voltage-gated ion channel comprising the VSD, such as inhibiting proton transport by Hv1. In some embodiments, the compounds according to the invention comprise at least one guanidine moiety in a five-membered aromatic ring. 2. The method of claim 1 , wherein said compound comprises at least one member selected from the group consisting of a 2-aminobenzimidazole claim 1 , a 2-guanidinobenzimidazole claim 1 , a 2-guanidino-4-methylquinazoline claim 1 , 1-(1 claim 1 ,3-ben-zothiazol-2-yl)guanidine claim 1 , and a 5-chloro-2-guanidinobenzimidazole.3. The method of claim 1 , wherein said compound comprises at least one member selected from the group consisting of a 2-guanidinobenzimidazole claim 1 , a 1-(1 claim 1 ,3-ben-zothiazol-2-yl)guanidine claim 1 , and a 5-chloro-2-guanidinobenzimidazole.4. The method of claim 1 , wherein said compound comprises 2-guanidinobenzimidazole.5. The method of claim 1 , wherein said compound comprises 1-(1 claim 1 ,3-ben-zothiazol-2-yl)guanidine.6. The method of claim 1 , wherein said compound comprises 5-chloro-2-guanidinobenzimidazole. The present application claims the benefit of U.S. Provisional Patent Application Ser. No. 61/754,906, which is hereby incorporated by reference in its entirety and which was filed Jan. 21, 2013.This invention was made in part with United States Government support under Grant No. R01GM098973, awarded by the National Institutes of Health. The U.S. Government has certain rights in this invention.Embodiments of the present invention relate to voltage sensing domains (VSD) of voltage-gated ...

Подробнее
Номер записи: 75
14-07-2016 дата публикации

METHOD FOR PRODUCING ENGINEERED HEART MUSCLE (EHM)

Номер: US20160201034A1
Автор: HUDSON James, TIBURCY Malte, Zimmermann Wolfram-Hubertus
Принадлежит: GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFF ENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN

The present invention provides a new method for producing Engineered Heart Muscle (EHM) under chemically fully defined conditions and compounds all compatible with GMP regulations. The resulting human myocardium generates force and shows typical heart muscle properties. 115-. (canceled)16. A method for producing engineered heart muscle (EHM) , the method comprising the steps of:(i) providing a serum-free reconstitution mixture in one or more moulds, said reconstitution mixture comprising (a) a serum-free minimum essential medium; (b) a serum-free supplement resulting in a final concentration of 0.5-50 mg/ml albumin, 1-100 μg/ml transferrin, 0.1-10 μg/ml ethanol amine, 0.003-0.3 μg/ml sodium selenite, 0.4-40 μg/ml L-Carnitine HCl, 0.1-10 μg/ml Hydrocortisone, 0.05-5 μl/ml Fatty acid supplement, 0.0001-0.1 μg/ml triodo-L-thyronine (T3) and 0.2-2 mg/ml collagen; and (c) a mixture of human cardiac myocytes and human non-myocytes, wherein 20 to 80% of the total cell mixture are cardiac myocytes; wherein the reconstitution mixture has a pH of 7.2 to 7.6;(ii) culturing the serum-free reconstitution mixture in said one or more moulds, whereby the serum-free reconstitution mixture is allowed to condense for at least 15 min;{'sup': '2+', '(iii) culturing the mixture obtained in step (ii) in said one or more moulds in a serum-free EHM culture medium until the mixture condenses to at least 50% of its original thickness, wherein said EHM culture medium comprises (a) a basal medium comprising 0.5-3 mmol/L Ca; (b) a serum-free supplement as defined in (i)(b); (c) 0.5-10 mmol/L L-glutamine; (d) 0.01-1.0 mmol/L ascorbic acid; (e) 1-100 ng/ml IGF-1; and (f) 1-10 ng/ml TGFβ1;'}(iv) culturing the mixture obtained in step (iii) under mechanical stretching in a serum-free EHM culture medium as defined in step (iii) (a)-(f), whereby force-generating EHM is formed.17. The method of claim 16 , wherein the minimum essential medium in step (i) claim 16 , in step (iii) claim 16 , or both in ...

Подробнее
Номер записи: 76
13-07-2017 дата публикации

Media for Cell Culture

Номер: US20170198251A1
Автор: Adam Elhofy, Allan Weber
Принадлежит: Bio-Ess Laboratories LLC, Essential Pharmaceuticals LLC

The present disclosure relates, in general, to a media, e.g., a serum replacement, media supplement, complete media or cryopreservation media, comprising a base physiological buffer and liposomes comprising cholesterol, phosphatidylcholine and fatty acids. It is contemplated that media provides advantages to improve cell growth in culture compared to cells cultured not using the serum replacement described herein.

Подробнее
Номер записи: 77
30-07-2015 дата публикации

Generation of Patient-Specific Differentiated Cell Types by Epigenetic Induction

Номер: US20150210985A1
Автор: Thiru Venkat Gopal
Принадлежит: Individual

Disclosure of a mammalian cytoplasmic donor cell line. Disclosure of a patient specific cell line. Methods to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated mammalian embryonic cell line. Methods to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated human cancer cell. Methods to obtain a patient specific cell line of a cell type similar to a mammalian cytoplasmic donor cell line by functionally enucleating the mammalian cytoplasmic donor cell line and fusing the functionally enucleated mammalian cytoplasmic donor cell line with a differentiated cell obtained from the patient. A method of treatment of a human patient by administering the patient-specific cell line to the patient.

Подробнее
Номер записи: 78
18-06-2020 дата публикации

Compositions and methods for stabilizing susceptible compounds

Номер: US20200190465A1
Автор: Bruce Branchaud, Richard Fike, Shawn Barrett
Принадлежит: Life Technologies Corp

Methods for increasing the stability of, or protecting, labile components such as ethanolamine, growth factors, vitamins, etc., in compositions such as a cell culture medium. Stability of the labile compound is increased either, by derivatization of the labile compound with chemicals, or by sequestering the labile compound. Sequestering can be done either by encapsulation within a microcapsule, or by the use of sequestering agents. Encapsulation includes the encapsulation of dendrimers complexes of susceptible compounds within the microcapsule, thereby providing the controlled release of the susceptible compound that was protected. These methods may improve and extend storage conditions of compositions comprising the labile compounds, improve shipping and handling of compositions comprising the labile compounds, such as dry media formulations, at room temperature rather than at lower temperatures thereby decreasing shipping costs. Stabilization of labile compounds in compositions such as dry format media can be viewed as a contribution to green technology.

Подробнее
Номер записи: 79
25-06-2020 дата публикации

Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof

Номер: US20200199539A1
Автор: Douglas A. Melton, Mads GÜRTLER
Принадлежит: Harvard College

Disclosed herein are methods for generating SC-β cells using chemically defined, completely serum free media, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

Подробнее
Номер записи: 80
05-08-2021 дата публикации

STEM CELL DERIVED ISLET DIFFERENTIATION

Номер: US20210238553A1
Автор: Harb George, Pagliuca Felicia J., Ye Lillian
Принадлежит:

Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells. 1198-. (canceled)199. A composition comprising PDX1-positive pancreatic progenitor cells and a protein kinase C (PKC) activator.200. The composition of claim 199 , wherein said PKC activator is selected from the group consisting of: Phorbol 12 claim 199 ,13-dibutyrate (PDBU) claim 199 , enzastaurin claim 199 , CHIR-98014 claim 199 , LY2157299 claim 199 , MK-0752 claim 199 , BMS-833923 claim 199 , avagacestat claim 199 , R04929097 claim 199 , DAPT (GSI-IX) claim 199 , hesperetin claim 199 , tofacitinib claim 199 , APTSTAT3-9R claim 199 , SB216763 claim 199 , CHIR-99021 claim 199 , semagacestat claim 199 , GF109203X claim 199 , repSox claim 199 , Go 6983 claim 199 , sotrastaurin claim 199 , LGK-974 claim 199 , PD173955 claim 199 , Ro31-8220 claim 199 , AZD1080 claim 199 , LY411575 claim 199 , and YO-010207.201. The composition of claim 199 , wherein said PKC activator comprises Phorbol 12 claim 199 ,13-dibutyrate (PDBU).202. The composition of claim 199 , wherein said composition comprises about 0.1 μM to about 1 μM of said PKC activator.203. The composition of claim 199 , wherein said PDX1-positive pancreatic progenitor cells comprise PDX1-positive claim 199 , NKX6.1− negative cells.204. The composition of claim 199 , wherein said PDX1-positive pancreatic progenitor cells comprise PDX1-positive claim 199 , NKX6.1− positive cells.205. The composition of claim 199 , wherein the composition further comprises a growth factor from the fibroblast growth factor (FGF) family.206. The composition of claim 205 , wherein the growth factor from the FGF family is selected from the group consisting ...

Подробнее
Номер записи: 81
09-08-2018 дата публикации

NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL

Номер: US20180222898A1
Автор: Merikapudi Gayatri S., MUTHUPPALANIAPPAN Meyyappan, Vakkalanka Swaroop K., Viswanadha Srikant
Принадлежит:

Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer. 167-. (canceled)69. The method of claim 68 , wherein the autoimmune disorder is multiple sclerosis claim 68 , chronic obstructive pulmonary disease claim 68 , chronic obstructive airway disease claim 68 , or psoriasis.70. The method of claim 68 , wherein the subject is a human subject.71. The method of claim 69 , wherein the subject is a human subject.72. A method of modulating store-operated calcium (SOC) channel activity comprising contacting the SOC channel complex claim 69 , or portion thereof claim 69 , with a compound N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide or a pharmaceutically acceptable salt thereof.73. A method of modulating calcium release activated calcium channel (CRAC) activity in a mammal comprising administering to the mammal a compound N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide or a pharmaceutically acceptable salt thereof.74. A method of inhibiting store-operated calcium entry (SOCE) activation of nuclear factor of activated T cells (NFAT) in a mammal comprising administering to the mammal a compound N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide or a pharmaceutically acceptable salt thereof.75. A method of decreasing cytokine release by inhibiting the SOCE activation of NFAT in a mammal comprising administering to the mammal a compound N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide or a pharmaceutically acceptable salt thereof.76. A method of inhibiting immune cell ...

Подробнее
Номер записи: 82
10-08-2017 дата публикации

METHODS OF CELL CULTURE

Номер: US20170226553A1
Автор: Prentice Holly
Принадлежит:

Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described. 135-. (canceled)36. A method of producing an adalimumab preparation having a target value of one or more of fucosylated glycans , galactosylated glycans , high mannose glycans , and sialylated glycans , the method comprising:(a) providing a cell genetically engineered to express adalimumab;(b) culturing the cell in a culture medium comprising 0.1 mg/L to 10 mg/L putrescine under conditions in which the cell expresses the adalimumab; and wherein the target value of fucosylated glycans, galactosylated glycans, or sialylated glycans is a level at least 10% higher than a level of fucosylated glycans, galactosylated glycans, or sialylated glycans in an adalimumab preparation produced by culturing the cell in the medium not comprising 0.1 mg/L to 10 mg/L putrescine; or', 'wherein the target value of high mannose glycans is a level at least 10% lower than a level of high mannose glycans in an adalimumab preparation produced by culturing the cell in the medium not comprising 0.1 mg/L to 10 mg/L putrescine., '(c) harvesting a preparation of the adalimumab produced by the cell that meets the target value of the one or more of fucosylated glycans, galactosylated glycans, high mannose glycans, and sialylated glycans,'}37. The method of claim 36 , wherein the target value is a level of one or more of fucosylated glycans claim 36 , galactosylated glycans claim 36 , high mannose glycans claim 36 , and sialylated glycans in a reference preparation of adalimumab.38. The method of claim 36 , further comprising evaluating a level of one or more of fucosylated glycans claim 36 , galactosylated glycans claim 36 , high mannose glycans claim 36 , and sialylated glycans in the adalimumab preparation.39. The method of claim 36 , wherein the target value is one or more of:(a) 70% to 100% fucosylated glycans;(b) 1% to 95% galactosylated glycans;(c) ...

Подробнее
Номер записи: 83
25-07-2019 дата публикации

Systems and methods for microbial production

Номер: US20190225993A1
Автор: Jianhua SONG, Qingye Jiang, Weiwei Zhao, Xuefeng Wang
Принадлежит: Icell Sustainable (shanghai) Nutrition Co Ltd

Methods to produce microbial biomass are provided. The methods involve the inoculation of a liquid growth medium including a controlled substrate with a microbial inoculum and incubation under conditions that are suitable for the production of biomass. The biomass and/or the liquid growth medium may be used to produce valuable products including food and feed products.

Подробнее
Номер записи: 84
26-08-2021 дата публикации

CELL CULTURE MEDIUM FOR EUKARYOTIC CELLS

Номер: US20210261913A1
Автор: Chen John, Golden Nathaniel, Loney Theodore, Scott Carolyn, Xue Wei
Принадлежит:

Cell culture media are provided herein as are methods of using the media for cell culture and protein production from cells. 1. A method for culturing eukaryotic cells for increasing production of a protein , comprising the steps of:culturing cells in a defined cell culture medium;supplementing the cell culture medium with nicotinamide, wherein concentration of the nicotinamide is about 50 nM to about 2000 nM; andproducing a protein in the eukaryotic cells,wherein the supplementation with nicotinamide increases a titer of the protein.2. The method of claim 1 , wherein the titer of the protein is at least about 2% greater than another method with a cell culture medium that does not have at least about 50 nM nicotinamide.3. The method of claim 1 , wherein the eukaryotic cells include at least one selected from the group consisting of: Baby Hamster Kidney cell lines claim 1 , Chinese Hamster Ovary cell lines claim 1 , Murine myeloma cell lines claim 1 , Mouse myeloma cell lines claim 1 , Human embryonic kidney cell lines claim 1 , Human-retina-derived cell lines claim 1 , and Amniocyte cell lines.4. The method of claim 1 , wherein the protein is secreted in the medium.5. The method of claim 1 , wherein the cell culture medium does not have a protein derived from an animal.6. The method of claim 1 , wherein the cell culture medium is a serum-free medium.7. The method of claim 1 , wherein the cell culture medium is a chemically-defined medium.8. A method for producing a protein claim 1 , comprising:introducing into a cell a nucleic acid comprising a nucleotide sequence encoding a protein;culturing the cell in a cell culture medium comprising at least about 50 nM nicotinamide or at least about 10 nM 5-methythioadenosine; andproducing the protein in the cell. The present invention generally pertains to a cell culture medium for eukaryotic cells and the production of natural and recombinant products derived therefrom.Cell culture manufacturing technology is widely used for ...

Подробнее
Номер записи: 85
23-08-2018 дата публикации

Improved method for ex vivo expansion CD34+HSPCs into NK cells using an aryl hydrocarbon receptor antagonist

Номер: US20180237749A1
Автор: Dolstra Harmen
Принадлежит: Stichting Katholieke Universiteit

The present invention relates to the field of medicine, specifically the field of treatment of cancer. More specifically, the invention relates to a method for the ex vivo production of a population of highly functional NK cells from CD34-positive cells, to a population of highly functional NK cells obtained and to the use of such population of highly functional NK cells for adoptive cell therapy. 115.-. (canceled)16. A method for the ex vivo production of a population of highly functional NK cells from CD34-positive cells comprising culturing CD34-positive cells in an expansion medium and subsequently culturing the expanded CD34-positive cells in a differentiation medium , wherein the expansion medium comprises an aryl hydrocarbon receptor antagonist.17. The method of claim 16 , wherein the CD34-positive cells are peripheral blood claim 16 , bone marrow or umbilical cord blood-derived CD34-positive cells.18. The method of claim 16 , with the proviso that the expansion medium and/or the differentiation medium do not comprise a glycosaminoglycan and/or do not comprise G-CSF claim 16 , GM-CSF and/or IL-6.19. The method of claim 16 , wherein culturing CD34-positive cells in an expansion medium and subsequently culturing the expanded CD34-positive cells in a differentiation medium comprises:culturing in an expansion medium comprising IL-7, SCF, TPO, Flt3L and an aryl hydrocarbon receptor antagonist,further culturing in a first differentiation medium comprising Il-7, SCF, Flt3L, IL-15 and an aryl hydrocarbon receptor antagonist,culturing in a second differentiation medium comprising IL-7, SCF and IL-15.20. The method of claim 19 , wherein the first differentiation medium and/or the second differentiation medium further comprises IL-2 or IL-12.21. The method of claim 16 , wherein the aryl hydrocarbon receptor antagonist is one selected from the group consisting of SR1 claim 16 , CH-223191 claim 16 , GNF351 claim 16 , 6 claim 16 ,2′ claim 16 ,4′trimethoxyflavone and ...

Подробнее
Номер записи: 86
10-09-2015 дата публикации

Method of Enhancing Cell Growth Using Alkyl-Amine-N-Oxide (AANOX)

Номер: US20150252321A1
Автор: Roy Sylvain
Принадлежит:

The present invention relates to a method to enhance cell growth in culture comprising adding an alkyl-amine-n-oxide (AANOx), such as dodecyldimethylamine oxide (DDAO), into the culture medium in an amount sufficient to improve cell growth. 119-. (canceled)20. A cell culture media comprising alkyl-amine-n-oxide (AANOx) in an amount sufficient to enhance cell growth when used in the culture media.21. The media of wherein the AANOx is dodecyldimethylamine oxide (DDAO) or a related analyte.22. The media of wherein the amount of AANOx is between about 4 and about 80 ppb.23. The media of wherein the amount of AANOx is between about 4 and about 50 ppb.24. The media of wherein the amount of AANOx is between about 10 ppb and about 40 ppb.25. The media of wherein the AANOx is not derived from a soy hydrolysate preparation.26. The media of wherein the AANOx is derived from a soy hydrolysate preparation.27. The media of claim 20 , wherein the AANOx is a DDAO-related analyte having an alkyl chain selected from the group consisting of a C10 claim 20 , C12 claim 20 , C14 claim 20 , and C16 alkyl.28. The media of claim 27 , wherein the DDAO-related analyte is selected from the group consisting of dimethyl-tetradecyl-amine-oxide or dimethyl-hexadecyl-amine-oxide.29. The media of claim 20 , wherein the culture media is animal protein-free media.30. The media of claim 20 , wherein the culture media comprises animal protein.31. The media of wherein the cells are mammalian cells.32. The media of claim 20 , wherein the cells are selected from the group consisting of BSC cells claim 20 , LLC-MK cells claim 20 , CV-1 cells claim 20 , COS cells claim 20 , VERO cells claim 20 , MDBK cells claim 20 , MDCK cells claim 20 , CRFK cells claim 20 , RAF cells claim 20 , RK cells claim 20 , TCMK-1 cells claim 20 , LLCPK cells claim 20 , PK15 cells claim 20 , LLC-RK cells claim 20 , MDOK cells claim 20 , BHK-21 cells claim 20 , CHO cells claim 20 , NS-1 cells claim 20 , MRC-5 cells claim 20 , WI-38 ...

Подробнее
Номер записи: 87
23-07-2020 дата публикации

METHOD FOR PRODUCING ENGINEERED HEART MUSCLE (EHM)

Номер: US20200231934A1
Автор: HUDSON James, TIBURCY Malte, Zimmermann Wolfram-Hubertus
Принадлежит: GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN

The present invention provides a new method for producing Engineered Heart Muscle (EHM) under chemically fully defined conditions all compatible with GMP regulations. The resulting human myocardium generates force and shows typical heart muscle properties. 1. A method for producing engineered heart muscle (EHM) , the method comprising the steps of:(i) providing a serum-free reconstitution mixture in one or more moulds, said reconstitution mixture comprising (a) a serum-free minimum essential medium; (b) a serum-free supplement resulting in a final concentration of 0.5-50 mg/ml albumin, 1-100 μg/ml transferrin, 0.1-10 μg/ml ethanol amine, 0.003-0.3 μg/ml sodium selenite, 0.4-40 μg/ml L-Carnitine HCl, 0.1-10 μg/ml Hydrocortisone, 0.05-5 μl/ml Fatty acid supplement, 0.0001-0.1 μg/ml triodo-L-thyronine (T3) and 0.2-2 mg/ml collagen;and (c) a mixture of human cardiac myocytes and human non-myocytes, wherein 20 to 80% of the total cell mixture are cardiac myocytes;wherein the reconstitution mixture has a pH of 7.2 to 7.6;(ii) culturing the serum-free reconstitution mixture in said one or more moulds, whereby the serum-free reconstitution mixture is allowed to condense for at least 15 min;{'sup': '2+', '(iii) culturing the mixture obtained in step (ii) in said one or more moulds in a serum-free EHM culture medium until the mixture condenses to at least 50% of its original thickness, wherein said EHM culture medium comprises (a) a basal medium comprising 0.5-3 mmol/L Ca; (b) a serum-free supplement as defined in (i)(b); (c) 0.5-10 mmol/L L-glutamine; (d) 0.01-1.0 mmol/L ascorbic acid; (e) 1-100 ng/ml IGF-1; and (f) 1-10 ng/ml TGFβ1; and'}(iv) culturing the mixture obtained in step (iii) under mechanical stretching in a serum-free EHM culture medium as defined in step (iii) (a)-(f), whereby force-generating EHM is formed.2. The method of claim 1 , wherein the minimum essential medium in step (i) claim 1 , in step (iii) claim 1 , or both in step (i) and step (iii) is selected ...

Подробнее
Номер записи: 88
01-09-2016 дата публикации

CELL CULTURE MEDIUM AND BIOPROCESS OPTIMIZATION

Номер: US20160251614A1
Автор: BRITO-ROBINSON Teresa, BURNETTE Miranda, LI JUN, Zartman Jeremiah
Принадлежит: University of Notre Dame du Lac

The invention provides a chemically defined cell culture media and methods of using the media. The invention also provides an inverse screen to identify small molecules and synergies stimulating proliferation in a chemically defined medium. In this chemical-genetics approach, a compound-protein interaction data-base is used to systematically score genetic targets on a screen-wide scale to extract further information about cell growth. Validated factors were investigated for their ability to maintain cell growth over multiple passages in the chemically defined medium (CDM). Polyamines were identified as important components that enables the CDM to support the long-term maintenance of C1.8 cells and Kc cells (such as Kc167 cells). Our cumulative target scoring approach improves on traditional chemical-genetics methods and is extensible to biological processes in other species. 1Drosophila. An aqueous chemically defined media for supporting long-term growth of cell lines , the media comprising ZO media supplemented with insulin , a disaccharide , ascorbic acid , and at least one of glutamine and glutamate , wherein the pH of the media is about 6 to about 8.2. The media of comprising about 95% to about 99% water.3. The media of wherein the insulin is present at a concentration of at least about 1 ng μg/mL.4. The media of wherein the disaccharide is present at a concentration of at least about 10 mM.5. The media of wherein the ascorbic acid is present at a concentration of at least about 40 ng/mL.6. The media of wherein the ascorbic acid is in the form of L-ascorbic acid 2-phosphate sesquimagnesium salt hydrate.7. The media of wherein the glutamine is in the form of a dipeptide.8. The media of wherein at least one of glutamine and glutamate is present at a concentration of at least about 5 μg/mL.9. The media of wherein the pH is about 6.5 to about 7.3.10. The media of further comprising a polyamine compound.11. The media of wherein the polyamine compound is present at a ...

Подробнее
Номер записи: 89
07-09-2017 дата публикации

HUMAN DISC TISSUE

Номер: US20170253859A1
Автор: Akbar Umar, Duntsch Christopher, Kukekov Valery
Принадлежит:

This invention provides disc stem cells, processes for obtaining and culturing disc stem cells, and methods for repairing damaged or diseased disc tissue comprising the use of the disc stem cells of the invention. 1a. suspending a sphere-like cluster of disc stem cells or an isolated disc stem cell from said sphere-like cell cluster in a medium comprising 6-10% serum, basic fibroblast growth factor (bFGF), and epidermal growth factor (EGF) and lacking methylcellulose;b. distributing the suspension onto ultra-low binding culture plates; andc. culturing said suspension for 8-16 days to produce a mature sphere of heterogeneous morphology having a diameter of roughly 100-600 microns, thereby amplifying and enriching a disc stem cell population.. A method of amplifying and enriching a disc stem cell population comprising the steps of: This application is a continuation of U.S. patent application Ser. No. 13/985,204, filed Mar. 21, 2014, which is a national stage application of PCT Patent Application No. PCT/US2012/025066, filed Feb. 14, 2012, which claims priority to U.S. Provisional Patent Application No. 61/442,315, filed Feb. 14, 2011 and U.S. patent application Ser. No. 13/113,599, filed May 23, 2011, which is a continuation-in-part of U.S. patent application Ser. No. 12/216,544, which claims priority to U.S. Provisional Patent Application No. 60/929,792; all of which are incorporated by reference herein in their entirety.This invention provides disc stem cells, processes for obtaining and culturing disc stem cells, and methods for repairing damaged or diseased disc tissue comprising the use of the disc stem cells of the invention.Neck and lower back pain from degeneration of the spinal disc joint constitutes a common and significant health and economic burden. Indeed, roughly 80% of adults will experience neck and lower back pain at some point in their lives due to intervertebral degeneration. Intervertebral disc degeneration is a product of lifelong, slow, and ...

Подробнее
Номер записи: 90
15-09-2016 дата публикации

NEW MEDIUM FOR HIGH PERFORMANCE MAMMALIAN FED-BATCH CULTURES

Номер: US20160264940A1
Автор: Broly Herve, Jordan Martin, PERILLEUX ARNAUD, ROUILLER YOLANDE, STETTLER MATTHIEU
Принадлежит:

The present invention relates to new serum- and protein-free culture media. These media are high performance culture media, which notably improve mammalian fed-batch cultures. The present invention also relates to methods for preparing and/or designing the medium, and methods of use thereof. 1. A cell culture medium comprising NaHPO , L-Leucine , L-Lysine , L-Methionine , L-Glutamic acid , L-phenylalanine , L-proline , L-threonine , L-tryptophan , L-Valine , magnesium sulfate , calcium chloride , myo-inositol , sodium pyruvate , D-Biotin , choline chloride , L-Aspargine , folic acid , niacinamide (B3) , D-pantothenic acid×½Ca , L-Serine , potassium chloride , pyridoxine , L-Aspartic acid , riboflavin , thiamine , ferric ammonium citrate , vitamin B12 , hypoxanthine , thymidine , putrescine , ethanolamine , zinc sulfate , cupric sulfate , pluronic , L-tyrosine , sodium selenite , L-arginine , L-Cysteine , L-Histidine and L-Isoleucine , wherein the medium is serum and protein free.2. The medium according to comprising: 1.7 to 10 mM of NaHPO claim 1 , 2 to 9 mM of L-Leucine claim 1 , 1 to 6 mM of L-Lysine claim 1 , 0 to 3 mM of Glycine claim 1 , 0.4 to 2 mM of L-Methionine claim 1 , 1 to 4 mM of L-Glutamic acid claim 1 , 0.5 to 3 mM of L-phenylalanine claim 1 , 0.7 to 6 mM of L-proline claim 1 , 0.7 to 6 mM of L-threonine claim 1 , 0.5 to 2 mM of L-tryptophan claim 1 , 1 to 7 mM L-Valine claim 1 , 0.1 to 1.5 mM of Magnesium Sulfate claim 1 , 0.1 to 1.05 mM of Calcium Chloride claim 1 , 0.07 to 0.7 mM of myo-Inositol claim 1 , 0.8 to 4 mM of Sodium pyruvate claim 1 , 0.0008 to 0.01 mM of D-Biotin claim 1 , 0.1 to 1 mM of Choline Chloride claim 1 , 3 to 9 mM of L-Aspargine claim 1 , 0.006 to 0.04 mM of Folic acid claim 1 , 0.03 to 0.15 mM of Niacinamide (B3) claim 1 , 0.015 to 0.15 mM of D-pantothenic acid×½Ca claim 1 , 1 to 8 mM of L-Serine claim 1 , 1 to 10 mM of Potassium Chloride claim 1 , 0.005 to 0.05 mM of Pyridoxine claim 1 , 0.8 to 2.4 mM of L-Aspartic acid ...

Подробнее
Номер записи: 91
14-10-2021 дата публикации

METHODS, KITS, AND COMPOSITIONS FOR ENHANCING CELLULAR THERAPY

Номер: US20210317409A9
Автор: Azari Hassan, Lovaton Rolando, Mitchell Duane, Rahman Maryam
Принадлежит: University of Florida Research Foundation, Incorporated

Cell-based compositions and methods for targeting and treating human diseases, including cancers and infectious diseases, are provided, wherein exogenous intracellular sarcosine is used for improved delivery of the composition. 1. A composition comprising an antigen presenting cell (APC) ,wherein the cell comprises a receptor for presenting antigen and antigen bound to the receptor, and wherein the cell contains at least 0.1 pg of sarcosine.2. A composition comprising an antigen presenting cell (APC) , wherein the cell comprises a receptor for presenting antigen and antigen bound to the receptor , and wherein the APC is cultured in the presence of media containing sarcosine and/or the APC is electroporated with sarcosine.3. A cell culture composition comprising:liquid medium containing sarcosine in concentrations above physiological levels, andan antigen presenting cell (APC).4. The composition of claim 3 , wherein the APC has a receptor for presenting antigen and antigen bound to the receptor.5. The composition of claim 2 , wherein the sarcosine is above physiological levels in the cell.6. The composition of claim 1 , wherein the cell contains between about 0.1 and 15 pg of sarcosine.7. The composition of claim 2 , wherein the cell contains at least 0.1 pg of sarcosine.8. The composition of claim 1 , wherein the APC is a human cell.9. The composition of claim 1 , wherein the APC is a dendritic cell (DC).10. The composition of claim 1 , wherein the antigen is a disease-associated antigen.11. The composition of claim 10 , wherein the antigen is a human cytomegalovirus (CMV) antigen.12. The composition of claim 10 , wherein the disease-associated antigen is a tumor antigen.13. The composition of claim 10 , wherein the antigen is from total tumor RNA.14. The composition of claim 10 , wherein the antigen is a conserved mutation antigen or a patient-specific mutation antigen.15. The composition of claim 10 , wherein the tumor antigen is an antigen presented on or within ...

Подробнее
Номер записи: 92
04-12-2014 дата публикации

Pluripotent cell lines and methods of use thereof

Номер: US20140356455A1
Автор: Birgitt Schüle, Blake Byers, Branden John Cord, Ha Nam Nguyen, J. William Langston, James Anthony Byrne, Renee Ann Reijo Pera, Theodore D. Palmer
Принадлежит: Leland Stanford Junior University, Parkinsons Institute

Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided.

Подробнее
Номер записи: 93
04-12-2014 дата публикации

DIFFERENTIATING INDUCED PLURIPOTENT STEM CELLS INTO GLUCOSE-RESPONSIVE, INSULIN-SECRETING PROGENY

Номер: US20140356951A1
Автор: IKEDA Yasuhiro, Kudva Yogish C., Terzic Andre, Thatava Tayaramma
Принадлежит:

This document provides methods and materials related to differentiating iPS cells into glucose-responsive, insulin-secreting progeny. For example, methods and material for using indolactam V (ILV) and glucagon like peptide-1 (GLP-1) to produce glucose-responsive, insulin-secreting progeny from iPS cells are provided. 1. (canceled)2. A method for obtaining a population of glucose-responsive , insulin-secreting cells from a diabetic human , wherein said method comprises:(a) obtaining somatic cells from a diabetic human,(b) exposing said somatic cells to one or more polypeptides or nucleic acids encoding said one or more polypeptides to form induced pluripotent stem cells, wherein said one or more polypeptides are selected from the group consisting of a Oct3/4 polypeptide, a Sox family polypeptide, a Klf family polypeptide, a Myc family polypeptide, a Nanog polypeptide, and a Lin28 polypeptide, and(c) culturing said induced pluripotent stem cells with medium comprising indolactam V and glucagon like peptide-1 to obtain said population of glucose-responsive, insulin-secreting cells.3. The method of claim 2 , wherein said medium lacks serum.4. The method of claim 2 , wherein said medium lacks feeder cells.5. The method of claim 2 , wherein said medium lacks non-human feeder cells.6. The method of claim 2 , wherein said somatic cells are selected from the group consisting of skin claim 2 , lung claim 2 , heart claim 2 , stomach claim 2 , brain claim 2 , liver claim 2 , blood claim 2 , kidney claim 2 , and muscle cells.7. The method of claim 2 , wherein said induced pluripotent stem cells comprise exogenous nucleic acid encoding a human Oct4 polypeptide claim 2 , a human Sox2 polypeptide claim 2 , a human Klf4 polypeptide claim 2 , and a human c-Myc polypeptide.8. The method of claim 2 , wherein said medium comprises greater than 300 nM of indolactam V.9. The method of claim 2 , wherein said medium comprises greater than 55 nM of glucagon like peptide-1.10. The method of ...

Подробнее
Номер записи: 94
22-08-2019 дата публикации

SMAC Mimetic

Номер: US20190255139A1
Автор: CONDON Stephen M., DENG Yijun, LaPorte Matthew G., Rippin Susan R.
Принадлежит:

A SMAC mimetic and pharmaceutical compositions thereof and methods of use. 2. The method of wherein Compound 15 is administered by intravenous infusion.3. The method of wherein Compound 15 is administered by intravenous bolus.4. The method of claim 1 , wherein the administering of the effective amount of Compound 15 is done in combination with a second cancer therapy that is radiotherapy.5. The method of claim 4 , wherein the radiotherapy is applied just to the localized area involved with a tumor.6. The method of claim 5 , wherein the radiotherapy further comprises applying the radiotherapy to draining lymph nodes.7. The method of claim 4 , wherein the radiotherapy is teletherapy.8. The method of claim 4 , wherein the radiotherapy is sealed source radiotherapy.9. The method of claim 1 , wherein the administering of the effective amount of Compound 15 is done in combination with a second cancer therapy that is chemotherapy.10. The method of wherein the chemotherapy comprises administration of a platinum containing DNA modifying agent.11. The method of wherein the chemotherapy comprises administration of carboplatin claim 10 , cisplatin claim 10 , or oxaliplatin.12. The method of wherein the chemotherapy comprises administration of carboplatin.13. The method of claim 1 , wherein the administering of the effective amount of Compound 15 is done in combination with a second cancer therapy that is immunotherapy. This application is a divisional of U.S. application Ser. No. 16/019,589, which is a continuation of U.S. application Ser. No. 15/344,813 filed Nov. 7, 2016, which is a continuation of U.S. application Ser. No. 14/075,190, filed Nov. 8, 2013 (now abandoned), which is a continuation of U.S. application Ser. No. 13/611,274, filed Sep. 9, 2012, and issued as U.S. Pat. No. 8,603,816, which is a divisional of U.S. application Ser. No. 12/819,221, filed Jun. 20, 2010 and issued as U.S. Pat. No. 8,283,372, which is a non-provisional of U.S. Application Ser. No. 61/222, ...

Подробнее
Номер записи: 95
22-08-2019 дата публикации

PROCESS FOR IMPROVING THE DISSOLUTION BEHAVIOUR OF COMPONENTS IN AQUEOUS SOLUTIONS

Номер: US20190256819A1
Автор: LUBDA Markus, SALAZAR Andrew, von Hagen Joerg
Принадлежит: Merck Patent GmBH

The present invention relates to a process for improving the solubility or dissolution behaviour of components in an aqueous solution. The dissolution properties of a slowly/badly dissolving component can be positively affected by generating mixed particles of this component with another component which has a negative dissolution enthalpy. By preparing and adding such mixed particles solubility is improved without changing the chemical composition. 1. A method for improving the solubility of a dry mixture with a given composition bya) identifying the one or more poorly soluble components in the said dry mixtureb) preparing mixed particles comprising at least one poorly soluble component and one component with a negative enthalpy of solutionc) preparing the said dry mixture with improved solubility by mixing the one or more mixed particles generated in step b) with the other components of dry mixture2. Method according to claim 1 , characterized in that the one or more poorly soluble components are compounds with a solubility of less than 20 g/l in an aqueous solution comprising more than 100 g/l of dissolved components at 25° C.3. Method according to claim 1 , characterized in that the one or more components with a negative enthalpy of solution are selected from the following group:prolineCalcium Chloride, anhydrousMagnesium Sulfate, anhydrousCalcium Oxide, anhydrousSodium HydroxidePotassium Hydroxide or mixtures thereof.4. Method according to claim 1 , characterized in that the component with a negative dissolution enthalpy is proline.5. Method according to claim 1 , characterized in that the one or more poorly soluble components are selected from the group of leucine claim 1 , isoleucine claim 1 , valine and phenylalanine.6. Method according to claim 1 , characterized in that in step b) the preparation of the mixed particles is performed by spray drying claim 1 , lyophilisation or wet granulation.7. Method according to claim 1 , characterized in that in step b) ...

Подробнее
Номер записи: 96
21-09-2017 дата публикации

Animal Protein-Free Media for Cultivation of Cells

Номер: US20170267969A1
Автор: Dorner Friedrich, Grillberger Leopold, Mundt Wolfgang, Reiter Manfred
Принадлежит:

The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes.

Подробнее
Номер записи: 97
13-08-2020 дата публикации

HUMAN DISC TISSUE

Номер: US20200255806A1
Автор: Akbar Umar, Duntsch Christopher D., Kukekov Valery
Принадлежит:

This invention provides disc stem cells, processes for obtaining and culturing disc stem cells, and methods for repairing damaged or diseased disc tissue comprising the use of the disc stem cells of the invention. 1. A method of inhibiting , or decreasing the likelihood of damage to or disease of a cartilage-containing joint of a subject , comprising the steps of:a. suspending a sphere-like cluster of stem cells or an isolated stem cell from said sphere-like cluster in a medium comprising 6-10% serum, basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) and lacking methylcellulose, and wherein the stem cell is derived from skin, muscle, intestine, bone marrow, neural, liver, heart, lung, pancreas, articular cartilage, bone, thymus, thyroid, or lymph tissue;b. distributing the suspension onto ultra-low binding culture plates;c. culturing said suspension for 8-16 days to produce a mature sphere of heterogeneous morphology having a diameter of roughly 100-600 microns; andd. administering to said subject said mature sphere of heterogeneous morphology, thereby inhibiting, or decreasing the likelihood of damage to or disease of the cartilage-containing joint of said subject.2. The method of claim 1 , wherein the stem cell is derived from articular cartilage claim 1 , heart claim 1 , or bone3. The method of claim 1 , wherein the administration is percutaneous.4. The method of claim 1 , wherein the administration is directly to the joint of said subject as part of a surgical procedure.5. The method of claim 1 , wherein said joint is a hip joint.6. The method of claim 1 , wherein said joint is a knee joint.7. The method of claim 1 , wherein said joint is a spinal joint.8. The method of claim 1 , wherein said serum is present at a concentration of 10%.9. The method of claim 1 , wherein said bFGF is present at a concentration of 10 ng/ml.10. The method of claim 1 , wherein said EGF is present at a concentration of 10 ng/ml.11. A method of inhibiting claim 1 ...

Подробнее
Номер записи: 98
29-08-2019 дата публикации

METHODS AND COMPOSITIONS RELATED TO Th-1 DENDRITIC CELLS

Номер: US20190262442A1
Автор: DECKER William K., KOMANDURI Krishna V., SHPALL Elizabeth J., XING Dongxia
Принадлежит: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Certain embodiments of the invention are directed to methods for inducing an immunologic response to a tumor in a patient using mature dendritic cells transfected with a nucleic acid composition encoding one or more tumor antigens and loaded with a corresponding tumor antigen composition. 1. (canceled)2. The method of claim 31 , wherein the mature dendritic cells are selected for CD83 expression claim 31 , wherein the selected mature dendritic cells are enriched for cells expressing increased levels of CD83 as compared to reference dendritic cells contacted with a tumor antigen composition and not a nucleic acid composition.3. The method of claim 2 , wherein CD83 expression is at least 10-40% higher than the reference dendritic cells.4. The method of claim 31 , wherein the immature dendritic cells are subjected to negative selection using an agent that binds a non-target dendritic cell.5. The method of claim 4 , wherein the agent is an antibody that binds an HLA allele.6. The method of claim 5 , wherein the HLA allele is a HLA-DR claim 5 , HLA-DO claim 5 , or HLA-DQ.7. The method of claim 5 , wherein the HLA allele is HLA-DR.8. The method of claim 31 , wherein the immature dendritic cells are subjected to positive selection using an agent that binds a target immature dendritic cell.9. The method of claim 8 , wherein the agent binds CD40 claim 8 , CD83 claim 8 , IL-2P and/or TLR-4.10. The method of claim 31 , wherein the nucleic acid composition comprises total nucleic acid from a tumor source.11. The method of claim 31 , wherein the nucleic acid composition comprises mRNA isolated from a tumor source.12. The method of claim 11 , wherein the isolated mRNA is enriched for mRNA encoding tumor specific antigens.13. The method of claim 12 , wherein the isolated mRNA is subjected to mRNA subtraction using non-tumor cell RNA.14. The method of claim 31 , wherein the tumor antigen composition is an enriched tumor antigen composition.15. The method of claim 14 , wherein the ...

Подробнее
Номер записи: 99
06-10-2016 дата публикации

Generation of Patient-Specific Differentiated Cell Types by Epigenetic Induction

Номер: US20160289636A1
Автор: Gopal Thiru Venkat
Принадлежит:

Disclosure of a mammalian cytoplasmic donor cell line. Disclosure of a patient specific cell line. Methods to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated mammalian embryonic cell line. Methods to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated human cancer cell. Methods to obtain a patient specific cell line of a cell type similar to a mammalian cytoplasmic donor cell line by functionally enucleating the mammalian cytoplasmic donor cell line and fusing the functionally enucleated mammalian cytoplasmic donor cell line with a differentiated cell obtained from the patient. A method of treatment of a human patient by administering the patient-specific cell line to the patient. 1. A method of preparing a self-propagating dopaminergic neuron cell specific to a human patient , the method comprising:(a) obtaining a human cancer cell;(b) treating the human cancer cell with a DNA interchelating agent to obtain a DNA interchelating agent treated human cancer cell,(c) treating the DNA interchelating agent treated human cancer cell with an agglutinin to obtain an agglutinin-treated human cancer cell;(d) fusing the agglutinin-treated human cancer cell from step (c) with a human dopaminergic neuron cell to obtain a self-propagating human dopaminergic neuron cytoplasmic donor cell;(e) treating the self-propagating human dopaminergic neuron cytoplasmic donor cell from step (d) with a DNA interchelating agent to obtain a DNA interchelating agent treated human dopaminergic neuron cytoplasmic donor cell;(f) treating the DNA interchelating agent treated human dopaminergic neuron cytoplasmic donor cell from step (e) with an agglutinin to obtain an agglutinin-treated human dopaminergic neuron cytoplasmic donor cell;(g) fusing the agglutinin-treated human dopaminergic neuron cytoplasmic donor cell from step (f) with a histone deacetylase ...

Подробнее
Номер записи: 100